var title_f27_14_27872="Mononeuritis multiplex MPA";
var content_f27_14_27872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Muscle wasting caused by nerve infarctions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral atrophy of the muscle in the web space between the first and second metacarpal bones. The underlying diagnosis is microscopic polyangiitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27872=[""].join("\n");
var outline_f27_14_27872=null;
var title_f27_14_27873="2D TTE parasternal long axis pleural and pericardial effusion";
var content_f27_14_27873=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1239px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/88546/2D_TTE_parasternal_PE_video.mp4?title=2D+TTE+parasternal+long+axis+pleural+and+pericardial+effusion\" style=\"width:528px;height:368px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 591px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal long axis view showing both pleural and pericardial effusions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 571px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A small to moderate sized pericardial effusion is seen (adjacent to the left ventricle) as well as a posterior pleural effusion.",
"    <div class=\"footnotes\">",
"     RV: right ventricle; LV: left ventricle; Ao: aorta; LA: left ventricle; PE: pericardial effusion; Pl eff: pleural effusion.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27873=[""].join("\n");
var outline_f27_14_27873=null;
var title_f27_14_27874="Patient information: Ovarian cancer screening (The Basics)";
var content_f27_14_27874=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/26/27043\">",
"         Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/1/11283\">",
"         Patient information: Ovarian cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?40/34/41507\">",
"         Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/15/30963\">",
"         Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/63/11252\">",
"         Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/15/6386\">",
"         Patient information: Ovarian cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ovarian cancer screening (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ovarian-cancer-screening-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H24342053\">",
"      <span class=\"h1\">",
"       What is ovarian cancer screening?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ovarian cancer screening is a way in which doctors look for early signs of ovarian cancer in women who have no symptoms of the disease. To screen for ovarian cancer, doctors can do a blood test called CA 125, an imaging test called an ultrasound, or both. These tests are not very accurate, but doctors sometimes recommend them for women who are at high risk of ovarian cancer. Experts do NOT recommend ovarian cancer screening for women who are not at high risk.",
"     </p>",
"     <p>",
"      The goal of screening is to find cancer early, before it has a chance to grow, spread, or cause problems. Unfortunately, there is no good proof that screening for ovarian cancer actually helps women live longer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24342070\">",
"      <span class=\"h1\">",
"       How does ovarian cancer screening work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Screening can involve a blood test, an ultrasound, or both. The blood test used most often is called CA 125. Other tests are also available or being studied.",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         CA 125 blood tests",
"        </strong>",
"        &ndash; CA 125 is a protein in the blood that goes up when a woman has ovarian cancer. The trouble is, this protein also goes up when a woman has other health problems that do not involve cancer. The test can help find ovarian cancer, but it is not very accurate. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Pelvic ultrasound",
"        </strong>",
"        &ndash; During a pelvic ultrasound, an ultrasound technician will insert a small device similar to a tampon into your vagina. The device uses sound waves to create images of the inside of your body.",
"        <br/>",
"        <br/>",
"        Ultrasounds can find abnormal growths on the ovaries, but they cannot tell whether the growths are caused by cancer. Sometimes less serious health problems, or even normal changes that happen during a woman&rsquo;s menstrual cycle, can cause these &ldquo;growths&rdquo;.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24342085\">",
"      <span class=\"h1\">",
"       Who should be screened for ovarian cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is not clear who, if anyone, should be screened for ovarian cancer. For now, experts agree that:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Screening is NOT appropriate for women at low risk. This includes women who do not have a family history of ovarian cancer or a cancer gene (described below). &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Screening is sometimes appropriate for women who still have their ovaries and who are at high risk. This includes women who have a family history of ovarian cancer or a gene that increases their risk of ovarian cancer. Women at highest risk include those who have had genetic tests showing that they:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Carry genes known as the &ldquo;BRCA&rdquo; genes",
"       </li>",
"       <li>",
"        Have a genetic condition called Lynch syndrome (also called hereditary nonpolyposis colorectal cancer or &ldquo;HNPCC&rdquo;) &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have a family history of ovarian cancer or have genes that put you at risk, discuss the pros and cons of screening with your doctor. Decide, with input from your doctor, if screening is right for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24342102\">",
"      <span class=\"h1\">",
"       What are the benefits of being screened for ovarian cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main benefit of screening is that it might help doctors find cancer early, when it should be easier to treat. This might lower the chances of dying of ovarian cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24342119\">",
"      <span class=\"h1\">",
"       What are the drawbacks to being screened for ovarian cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main drawback of being screened is that it can lead to &ldquo;false positives,&rdquo; meaning that screening indicates that a woman might have cancer when she does not. This can lead to unneeded worry and to more tests. Sometimes, a false positive test could lead to unneeded surgery. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24342136\">",
"      <span class=\"h1\">",
"       What happens after screening?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After ovarian cancer screening, you should get a phone call or letter with your results. If you do not hear back about your results within 2 weeks, call your doctor or nurse's office. Do not assume that your screening test was normal if you hear nothing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24342153\">",
"      <span class=\"h1\">",
"       What if my screening test is abnormal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your test is abnormal, don't panic. Many women who have abnormal results turn out NOT to have ovarian cancer. You will need more tests to find out whether or not you actually have cancer.",
"     </p>",
"     <p>",
"      Most women with abnormal results find out they do not have cancer after further testing. But some women with abnormal results (in one study, about 1 in 3 women) need surgery to know for sure if they have cancer. This surgery is usually done through small incisions, using a tool called a &ldquo;laparoscope.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24342169\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/26/27043?source=see_link\">",
"       Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=see_link\">",
"       Patient information: Ovarian cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=see_link\">",
"       Patient information: Ovarian cancer screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"       Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=see_link\">",
"       Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"       Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/14/27874?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16188 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27874=[""].join("\n");
var outline_f27_14_27874=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24342053\">",
"      What is ovarian cancer screening?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24342070\">",
"      How does ovarian cancer screening work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24342085\">",
"      Who should be screened for ovarian cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24342102\">",
"      What are the benefits of being screened for ovarian cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24342119\">",
"      What are the drawbacks to being screened for ovarian cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24342136\">",
"      What happens after screening?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24342153\">",
"      What if my screening test is abnormal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24342169\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=related_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/26/27043?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=related_link\">",
"      Patient information: Ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=related_link\">",
"      Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=related_link\">",
"      Patient information: Ovarian cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_14_27875="Phenol: Drug information";
var content_f27_14_27875=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/43/32436?source=see_link\">",
"    see \"Phenol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Castellani Paint Modified [OTC];",
"     </li>",
"     <li>",
"      Cepastat&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Cepastat&reg; [OTC];",
"     </li>",
"     <li>",
"      Cheracol&reg; Spray [OTC];",
"     </li>",
"     <li>",
"      Chloraseptic&reg; Kids Sore Throat Spray [OTC];",
"     </li>",
"     <li>",
"      Chloraseptic&reg; Mouth Pain [OTC];",
"     </li>",
"     <li>",
"      Chloraseptic&reg; Sore Throat Gargle [OTC];",
"     </li>",
"     <li>",
"      Chloraseptic&reg; Sore Throat Spray [OTC];",
"     </li>",
"     <li>",
"      Pain-A-Lay&reg; [OTC];",
"     </li>",
"     <li>",
"      Phenaseptic [OTC];",
"     </li>",
"     <li>",
"      Phenol EZ&reg; [OTC];",
"     </li>",
"     <li>",
"      Ulcerease&reg; [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Formula 44&reg; Sore Throat [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F209038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      P &amp; S&trade; Liquid Phenol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F209044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anesthetic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F209039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sore throat:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     C��pastat&reg; Extra Strength, C��pastat&reg;: Up to 2 lozenges every 2 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cheracol&reg;, Pain-A-Lay&reg; Spray: Spray directly in throat; rinse for 15 seconds then expectorate; may repeat every 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Chloraseptic&reg;: Five sprays onto throat or affected area; may repeat every 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Chloraseptic&reg; Gargle, Chloraseptic&reg; Mouth Pain, Pain-A-Lay&reg; Gargle, Ulcerease&reg;: Gargle or swish for 15 seconds, then expectorate; may repeat every 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiseptic: Topical: Castellani Paint Modified: Apply small amount to affected area 1-3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F1987308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Sore throat:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 2-12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Chloraseptic&reg;: Three sprays onto throat or affected area; may repeat every 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Chloraseptic&reg; for Kids: Five sprays onto throat or affected area; may repeat every 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &gt;3 year (Ulcerease&reg;): Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 6-12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     C��pastat&reg; Extra Strength: Up to 1 lozenge every 2 hours as needed (maximum: 10 lozenges/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     C��pastat&reg;: Up to 1 lozenge every 2 hours as needed (maximum: 18 lozenges/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pain-A-Lay&reg; Gargle: Using gauze pad, apply 10 mL to affected area, or gargle or swish for 15 seconds, then expectorate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;12 years: C��pastat&reg; Extra Strength, C��pastat&reg;,Cheracol&reg;, Pain-A-Lay&reg; (spray/gargle), Chloraseptic&reg; (spray/gargle), Chloraseptic&reg; Mouth Pain: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F209040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cepastat&reg;: 14.5 mg (18s) [sugar free; contains menthol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cepastat&reg; Extra Strength: 29 mg (18s) [sugar free; contains eucalyptus oil, menthol; menthol-eucalyptus flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [gargle]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloraseptic&reg; Sore Throat Gargle: 1.4% (296 mL) [ethanol free, gluten free, sugar free; cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pain-A-Lay&reg;: 1.4% (236 mL) [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [mouthwash/gargle]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ulcerease&reg;: 0.6% (30 mL, 180 mL) [dye free, ethanol free, sugar free; contains glycerin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [refill for spray/gargle]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pain-A-Lay&reg;: 1.4% (532 mL) [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [spray]: 1.4% (177 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cheracol&reg; Spray: 1.4% (177 mL) [ethanol free, sugar free; contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloraseptic&reg; Kids Sore Throat Spray: 0.5% (177 mL) [ethanol free, gluten free, sugar free; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloraseptic&reg; Mouth Pain: 1.4% (29 mL) [ethanol free, gluten free, sugar free; cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloraseptic&reg; Sore Throat Spray: 1.4% (20 mL, 177 mL) [ethanol free, gluten free, sugar free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloraseptic&reg; Sore Throat Spray: 1.4% (177 mL) [ethanol free, gluten free, sugar free; cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloraseptic&reg; Sore Throat Spray: 1.4% (177 mL) [ethanol free, gluten free, sugar free; menthol flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pain-A-Lay&reg;: 1.4% (177 mL) [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenaseptic: 1.4% (177 mL) [sugar free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; Formula 44&reg; Sore Throat: 1.4% (177 mL) [contains menthol; cherry ice flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; Formula 44&reg; Sore Throat: 1.4% (177 mL) [contains menthol; honey-lemon ice flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Castellani Paint Modified: 1.5% (30 mL) [contains acetone, basic fuchsin, ethanol 13%, resorcinol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [colorless]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Castellani Paint Modified: 1.5% (30 mL) [contains acetone, ethanol 13%, resorcinol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Swab, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenol EZ&reg;: 89% (30s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Oral spray",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1987309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Allow to lozenge dissolve slowly in mouth. Spray should be allowed to remain in mouth for ~15 seconds, then expectorate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Castellani Paint Modified: May stain skin and clothing; apply to clean area",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F209032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of sore throat pain, mouth, gum, and throat irritations; antiseptic; topical anesthetic",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F209049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       C��pastat&reg; may be confused with Capastat&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1987305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; OTC labeling: Sore throat: Not for use &gt;7 days or if pain, redness, or irritation continues. If sore throat is severe, not for use &gt;2 days or if followed by fever, headache, rash, nausea, or vomiting. Oral gargles and sprays should not be swallowed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; OTC labeling: Topical antiseptic: Do not use in eyes, or apply to large areas of the body, deep or puncture wounds, animal bites or burns. Do not use for &gt;7 days; do not bandage affected area.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14315198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phenol is systemically absorbed following oral ingestion, inhalation, or application to the skin. Fetotoxic effects have been observed in animal reproduction studies (Bruce, 1987).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Castellani Paint Modified External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5% (29.57 mL): $32.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Pain-A-Lay Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.4% (236 mL): $11.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ulcerease Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6-1.5% (30 mL): $1.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Swab",
"     </b>",
"     (Phenol EZ Swabs External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     89% (30): $155.94",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F209035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bucoxol Spray (CO);",
"     </li>",
"     <li>",
"      Noraver (CO);",
"     </li>",
"     <li>",
"      Oily Phenol Inj (AU);",
"     </li>",
"     <li>",
"      Paoscle (JP);",
"     </li>",
"     <li>",
"      Phenolum liquefactum (PL)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bruce RM, Santodonato J, and Neal MW, \"Summary Review of the Health Effects Associated With Phenol,\"",
"      <i>",
"       Toxicol Ind Health",
"      </i>",
"      , 1987, 3(4):535-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/14/27875/abstract-text/3324392/pubmed\" id=\"3324392\" target=\"_blank\">",
"        3324392",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10209 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27875=[""].join("\n");
var outline_f27_14_27875=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209037\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209038\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209044\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209039\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987308\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209040\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209031\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209020\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987309\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209032\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209049\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987305\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315198\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323679\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209035\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10209\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10209|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/43/32436?source=related_link\">",
"      Phenol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_14_27876="Acarbose: Patient drug information";
var content_f27_14_27876=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acarbose: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     see \"Acarbose: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/46/25316?source=see_link\">",
"     see \"Acarbose: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Precose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Glucobay&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acarbose or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703498",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Diabetic acid problem, problems with food break down, inflammatory bowel disease, bowel block, liver disease, malabsorption syndrome, poor eating habits, or ulcers in the colon.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697115",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug with other high blood sugar (diabetes) drugs, use glucose (dextrose, D-glucose) or milk to treat low blood sugar. Table sugar may not work as fast.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be used alone or with other high blood sugar (diabetes) drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with the first bite of each meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it, after a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12256 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27876=[""].join("\n");
var outline_f27_14_27876=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129130\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129131\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014920\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014919\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014924\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014925\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014927\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014922\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014923\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014928\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014929\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=related_link\">",
"      Acarbose: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/46/25316?source=related_link\">",
"      Acarbose: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_14_27877="Liotrix: Patient drug information";
var content_f27_14_27877=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Liotrix: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38917?source=see_link\">",
"     see \"Liotrix: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/38/22118?source=see_link\">",
"     see \"Liotrix: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Thyrolar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Thyrolar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700809",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat obesity or for weight loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to add thyroid hormone to the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702398",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to liotrix or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3508599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Overactive thyroid gland or weak adrenal gland.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take iron products, antacids that have aluminum and magnesium, calcium carbonate, simethicone, sucralfate, Kayexalate&reg;, colestipol, or cholestyramine within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling more or less hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698381",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A change in weight without trying.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bothered by heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sweating a lot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698178",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Grouchy or touchy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698200",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leg cramps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain or loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach before breakfast.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10810 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27877=[""].join("\n");
var outline_f27_14_27877=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189131\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189132\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011956\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011958\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011957\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011962\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011963\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011965\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011960\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011961\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011966\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011967\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38917?source=related_link\">",
"      Liotrix: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/38/22118?source=related_link\">",
"      Liotrix: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_14_27878="Vibrio parahaemolyticus infections";
var content_f27_14_27878=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vibrio parahaemolyticus infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/14/27878/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27878/contributors\">",
"     J Glenn Morris, Jr, MD, MPH&amp;TM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/14/27878/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27878/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/14/27878/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27878/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/14/27878/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vibrio parahaemolyticus is a gram-negative bacterium that can cause seafood-associated diarrheal illness; it has also been associated with wound infections and septicemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    V. parahaemolyticus was first isolated in 1950 from clinical samples and \"shirasu\" (dried sardines) during an outbreak of gastroenteritis in Osaka, Japan. Over the next decade, similar organisms were recovered from vehicles such as raw fish, shellfish, and cucumbers in brine during a number of food-borne outbreaks in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis, epidemiology, clinical features, diagnosis, and treatment of V. parahaemolyticus infections will be reviewed here. Vibrio vulnificus, other \"non-cholera\" Vibrios, and Vibrio cholerae are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=see_link\">",
"     \"Vibrio vulnificus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link\">",
"     \"Overview of Vibrio cholerae infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18502?source=see_link\">",
"     \"Infections due to non-O1/O139 Vibrio cholerae\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenicity of V. parahaemolyticus has been correlated with production of thermostable direct hemolysin (Vp-TDH), which is responsible for the beta-hemolysis observed when the organisms are plated on a modified blood agar (Wagatsuma agar) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. This is known as the Kanagawa phenomenon, named after the region in Japan where it was discovered.",
"   </p>",
"   <p>",
"    The Kanagawa phenomenon was originally demonstrated in 96 percent of Japanese clinical isolates but in only 1 percent of environmental strains. In one study of human volunteers, Kanagawa-positive strains produced diarrhea, while Kanagawa-negative strains did not (even in doses of up to 10(9) organisms) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/7\">",
"     7",
"    </a>",
"    ]. Deletion of the Vp-TDH gene results in loss of enterotoxic activity in laboratory models [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second group of hemolysins, known as Vp-TDH-related hemolysins, or Vp-TRH, can be found in certain clinical isolates of V. parahaemolyticus. Many of these strains are phenotypically Kanagawa negative. Along the Pacific coast of the United States and in parts of Asia, there have been case clusters associated with V. parahaemolyticus strains that are urease positive but Kanagawa negative [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. These strains have almost always been shown to carry the genes for Vp-TRH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the majority of clinical isolates produce Vp-TDH",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Vp-TRH, in one study 6 percent of clinical samples lacked both toxin genes, suggesting the presence of additional virulence factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/13\">",
"     13",
"    </a>",
"    ]. Genomic studies have shown that some V. parahaemolyticus strains carry genes for the type III secretion system, which has been linked with pathogenicity in other diarrheal pathogens (eg, Shigella spp, Salmonella spp, enteropathogenic Escherichia coli, and other non-cholera Vibrios) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. This may be an additional virulence factor associated with a more invasive type of diarrhea due to V. parahaemolyticus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like other Vibrios, V. parahaemolyticus exists as a free-living bacterium in estuarine or marine environments and is a common seafood contaminant. Counts of the bacterium in the environment (and in oysters) tend to increase as water temperatures rise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Bacterial counts may also be influenced by salinity; higher counts are observed in regions of lower salinity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There was a global increase in the incidence of V. parahaemolyticus infections beginning in the mid-1990s, associated with the appearance of a new pandemic clonal group [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/22\">",
"     22",
"    </a>",
"    ]. Isolates in this group have a high degree of genetic similarity, albeit with a diversity of serotypes, including O3:K6, O4:K68, and O1:K untypable (O1:KUT) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. These isolates were first identified on the Indian subcontinent and subsequently have been identified in clinical and environmental samples from all continents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. They appeared in the late",
"    <span class=\"nowrap\">",
"     1990s/early",
"    </span>",
"    2000s along the western coast of South America, in an expansion reminiscent of the appearance of V. cholerae El Tor in South America in 1991. In both instances, spread of the pandemic microorganism from Asia to South America occurred in the setting of an El Nino weather event [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/31\">",
"     31",
"    </a>",
"    ]. In the late 2000s, the force of this pandemic began to wane. Global incidence rates remain high, and in reports from surveillance programs in the United States, the incidence appears to be increasing, from 0.01 to 0.06 per 100,000 persons in 1996 to 0.13 to 0.23 per 100,000 in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/32\">",
"     32",
"    </a>",
"    ]. In other countries, data suggest that rates are stable or declining [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    V. parahaemolyticus is most commonly transmitted by contaminated food. In the United States, V. parahaemolyticus has been responsible for a number of major food-borne disease outbreaks, often involving mishandling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cross-contamination of seafood after cooking. Commonly implicated vehicles include oysters, clams, and have traditionally included shrimp, crab, and, in one study in coastal areas of Texas and Louisiana, cooked crayfish [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/19,34-36\">",
"     19,34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    V. parahaemolyticus may also cause wound infections; these are most often associated with marine recreational activities (swimming, shore walking, boating) and, less commonly, with handling of seafood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the 345 sporadic V. parahaemolyticus infections reported to the Centers for Disease Control (CDC) between 1973 and 1998, 59 percent were associated with gastroenteritis, 34 percent were wound infections, 5 percent were associated with sepsis, and 2 percent involved other sites, including the ear, eye, urinary tract, and peritoneum (in a patient with acute appendicitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/35\">",
"     35",
"    </a>",
"    ]. A similar distribution of cases is reflected in the data for 2008 from the CDC Vibrio Surveillance System, shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef75467 \" href=\"UTD.htm?42/4/43086\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among 202 patients with gastroenteritis in the 1973-1998 case series, clinical manifestations included diarrhea (98 percent), abdominal cramps (89 percent), nausea (76 percent), vomiting (55 percent), and fever (52 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/35\">",
"     35",
"    </a>",
"    ]. Bloody diarrhea was reported in 29 percent of cases. [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Based on data from food-borne outbreaks, the median incubation period for gastroenteritis is 17 hours (range, 4 to 90 hours), with a median reported duration of illness of 2.4 days (range, 8 hours to 12 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/35\">",
"     35",
"    </a>",
"    ]. Somewhat milder symptomatology was reported in an oyster-associated outbreak in Alaska: fever (34 percent), vomiting (29 percent) and bloody diarrhea (7 percent); the median duration of symptoms was 5 days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wound infections associated with exposure of wounds to estuarine waters are generally mild. However, for patients with underlying conditions such as liver disease, alcoholism, or diabetes, cellulitis can be severe, with a reported 3 percent case fatality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/35,37\">",
"     35,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    V. parahaemolyticus can also cause septicemia, particularly in individuals with underlying liver disease (as with other Vibrios). Among 11 patients with sepsis for whom food histories were available in the 1973-1998 CDC case series, 10 (91 percent) had eaten raw oysters before onset of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/35\">",
"     35",
"    </a>",
"    ]. The case fatality rate for persons with septicemia was 29 percent in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18502?source=see_link\">",
"     \"Infections due to non-O1/O139 Vibrio cholerae\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=see_link\">",
"     \"Vibrio vulnificus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. parahaemolyticus grows well on blood agar and other nonselective media. Isolation from stool generally requires use of a selective medium, such as Thiosulfate Citrate Bile-salts Sucrose (TCBS). V. parahaemolyticus does not ferment sucrose; consequently, colonies on TCBS are blue-green in color. Species identification is based on standard biochemical tests; the accuracy may be improved with the addition of a few drops of 10 percent NaCl prior to inoculation. The laboratory should be alerted regarding cases in which V. parahaemolyticus is suspected so that the appropriate diagnostic techniques can be implemented.",
"   </p>",
"   <p>",
"    As noted above, most environmental V. parahaemolyticus isolates lack the genes necessary to cause illness in humans. Clinically significant isolates are hemolytic (have a positive Kanagawa reaction) or have a positive urease reaction. Confirmation that a strain is pathogenic requires use of PCR to screen for the presence of TDH and TRH genes; in general, this is a research tool [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume repletion is the most important element of therapy in patients with Vibrio gastroenteritis. The gastroenteritis caused by V. parahaemolyticus tends to be mild and self-limited. Antimicrobial therapy is reasonable in more severe cases, since among patients with cholera, antibiotic therapy is known to decrease the duration of diarrhea and the excretion of infectious organisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no controlled trials of therapy for gastroenteritis due to Vibrio parahaemolyticus. Therefore, antimicrobial therapy is guided by the same principles used for comparable clinical syndromes caused by other Vibrio species. Based on clinical trials in cholera and in vitro susceptibility data,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is a reasonable antibiotic choice; reasonable alternatives include fluoroquinolones and macrolides. The duration of therapy depends on the antibiotic chosen, as outlined separately for cholera (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of Vibrio cholerae infection\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Wound infections require debridement and antimicrobial therapy. Mild wound infections in patients who do not have significant underlying diseases generally respond well to local wound care and oral antibiotics (such as a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    or a fluoroquinolone). This approach is guided by the same principles used for comparable clinical syndromes caused by V. vulnificus. Duration of therapy is dictated by clinical response; most patients respond to 5 to 7 days of antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=see_link&amp;anchor=H12#H12\">",
"     \"Vibrio vulnificus infections\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with septicemia or wound infections in the setting of risk factors for septicemia require aggressive antimicrobial therapy, frequently in an ICU setting. The approach to choice of antibiotic therapy for such cases is as outlined for V. vulnificus: combination therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally twice daily), plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    (2 g intravenously every eight hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 g intravenously daily). Depending on clinical response and the degree of the patient&rsquo;s immunosuppression, two weeks (or more) of antimicrobial therapy may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=see_link&amp;anchor=H12#H12\">",
"     \"Vibrio vulnificus infections\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all Vibrios, risk of infection may be reduced by avoiding consumption of raw or undercooked shellfish, particularly during warm, summer months. Post-harvest treatments (mild heat treatment, freezing, hydrostatic pressure) can reduce V. parahaemolyticus counts in raw oysters, potentially reducing disease risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27878/abstract/43\">",
"     43",
"    </a>",
"    ]. Care must also be exercised to minimize mishandling of fish and shellfish and to avoid cross-contamination of cooked foods by raw seafood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12051994\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vibrio parahaemolyticus is a gram-negative bacterium that can cause seafood-associated diarrheal illness; it has also been associated with wound infections and septicemia. Gastroenteritis often occurs in the setting of mishandling",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cross-contamination of seafood after cooking. In these cases, clinical manifestations include diarrhea, abdominal cramps, nausea, vomiting, and fever. Wound infections associated with exposure of wounds to estuarine waters can be severe in the setting of liver disease, alcoholism, or diabetes. V. parahaemolyticus can also cause septicemia, particularly in individuals with underlying liver disease (as with other Vibrios). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenicity of V. parahaemolyticus has been correlated with production of thermostable direct hemolysin (Vp-TDH), which is responsible for the beta-hemolysis observed when the organisms are plated on a modified blood agar (Wagatsuma agar). This is known as the Kanagawa phenomenon, named after the region in Japan where it was discovered. A second group of hemolysins, known as Vp-TDH-related hemolysins, or Vp-TRH, can be found in certain clinical isolates of V. parahaemolyticus. Many of these strains are phenotypically Kanagawa negative. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      V. parahaemolyticus grows well on blood agar and other nonselective media. Isolation from stool generally requires use of a selective medium, such as Thiosulfate Citrate Bile-salts Sucrose (TCBS). V. parahaemolyticus does not ferment sucrose; consequently, colonies on TCBS are blue-green in color. Clinically significant isolates are hemolytic (have a positive Kanagawa reaction) or have a positive urease reaction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Volume repletion is the most important element of therapy in patients with Vibrio gastroenteritis. The gastroenteritis caused by V. parahaemolyticus tends to be mild and self-limited. More severe cases benefit from antimicrobial therapy; we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of wound infections requires debridement and antimicrobial therapy. We suggest a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      or fluoroquinolone for treatment of mild wound infections in patients who do not have risk factors for serious infection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of septicemia or wound infections in the setting of risk factors for septicemia requires aggressive antimicrobial therapy; intensive care management may also be needed. We suggest antimicrobial treatment with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      plus a third-generation cephalosporin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk of infection may be reduced by avoiding consumption of raw or undercooked shellfish, particularly during warm, summer months. Post-harvest treatments (mild heat treatment, freezing, hydrostatic pressure) can reduce V. parahaemolyticus counts in raw oysters, potentially reducing disease risk. Care must also be exercised to minimize mishandling of fish and shellfish and to avoid cross-contamination of cooked foods by raw seafood. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/1\">",
"      Morris JG Jr, Black RE. Cholera and other vibrioses in the United States. N Engl J Med 1985; 312:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/2\">",
"      Hlady WG, Klontz KC. The epidemiology of Vibrio infections in Florida, 1981-1993. J Infect Dis 1996; 173:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/3\">",
"      Joseph SW, Colwell RR, Kaper JB. Vibrio parahaemolyticus and related halophilic Vibrios. Crit Rev Microbiol 1982; 10:77.",
"     </a>",
"    </li>",
"    <li>",
"     Miwatani T, Takeda Y. Vibrio parahaemolyticus: A causative bacterium of food poisoning, Saikon Publishing Co, Tokyo 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/5\">",
"      Sakazaki R, Tamura K, Kato T, et al. Studies on the enteropathogenic, facultatively halophilic bacterium, Vibrio parahaemolyticus. 3. Enteropathogenicity. Jpn J Med Sci Biol 1968; 21:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/6\">",
"      Miyamoto Y, Kato T, Obara Y, et al. In vitro hemolytic characteristic of Vibrio parahaemolyticus: its close correlation with human pathogenicity. J Bacteriol 1969; 100:1147.",
"     </a>",
"    </li>",
"    <li>",
"     Sanyal SC, Sen PC. Human volunteer study on the pathogenicity of Vibrio parahaemolyticus. In: International Symposium on Vibrio parahaemolyticus, Saikon Publishing Company Ltd, Tokyo 1973. p.227.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/8\">",
"      Nishibuchi M, Fasano A, Russell RG, Kaper JB. Enterotoxigenicity of Vibrio parahaemolyticus with and without genes encoding thermostable direct hemolysin. Infect Immun 1992; 60:3539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/9\">",
"      Kelly MT, Stroh EM. Urease-positive, Kanagawa-negative Vibrio parahaemolyticus from patients and the environment in the Pacific Northwest. J Clin Microbiol 1989; 27:2820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/10\">",
"      Abbott SL, Powers C, Kaysner CA, et al. Emergence of a restricted bioserovar of Vibrio parahaemolyticus as the predominant cause of Vibrio-associated gastroenteritis on the West Coast of the United States and Mexico. J Clin Microbiol 1989; 27:2891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/11\">",
"      Suthienkul O, Ishibashi M, Iida T, et al. Urease production correlates with possession of the trh gene in Vibrio parahaemolyticus strains isolated in Thailand. J Infect Dis 1995; 172:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/12\">",
"      Okuda J, Ishibashi M, Abbott SL, et al. Analysis of the thermostable direct hemolysin (tdh) gene and the tdh-related hemolysin (trh) genes in urease-positive strains of Vibrio parahaemolyticus isolated on the West Coast of the United States. J Clin Microbiol 1997; 35:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/13\">",
"      Lynch T, Livingstone S, Buenaventura E, et al. Vibrio parahaemolyticus disruption of epithelial cell tight junctions occurs independently of toxin production. Infect Immun 2005; 73:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/14\">",
"      Makino K, Oshima K, Kurokawa K, et al. Genome sequence of Vibrio parahaemolyticus: a pathogenic mechanism distinct from that of V cholerae. Lancet 2003; 361:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/15\">",
"      Park KS, Ono T, Rokuda M, et al. Functional characterization of two type III secretion systems of Vibrio parahaemolyticus. Infect Immun 2004; 72:6659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/16\">",
"      Okada N, Iida T, Park KS, et al. Identification and characterization of a novel type III secretion system in trh-positive Vibrio parahaemolyticus strain TH3996 reveal genetic lineage and diversity of pathogenic machinery beyond the species level. Infect Immun 2009; 77:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/17\">",
"      Kelly MT, Stroh EM. Temporal relationship of Vibrio parahaemolyticus in patients and the environment. J Clin Microbiol 1988; 26:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/18\">",
"      Parveen S, Hettiarachchi KA, Bowers JC, et al. Seasonal distribution of total and pathogenic Vibrio parahaemolyticus in Chesapeake Bay oysters and waters. Int J Food Microbiol 2008; 128:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of Vibrio parahaemolyticus infections associated with eating raw oysters--Pacific Northwest, 1997. MMWR Morb Mortal Wkly Rep 1998; 47:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/20\">",
"      McLaughlin JB, DePaola A, Bopp CA, et al. Outbreak of Vibrio parahaemolyticus gastroenteritis associated with Alaskan oysters. N Engl J Med 2005; 353:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/21\">",
"      Martinez-Urtaza J, Lozano-Leon A, Varela-Pet J, et al. Environmental determinants of the occurrence and distribution of Vibrio parahaemolyticus in the rias of Galicia, Spain. Appl Environ Microbiol 2008; 74:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/22\">",
"      Nair GB, Ramamurthy T, Bhattacharya SK, et al. Global dissemination of Vibrio parahaemolyticus serotype O3:K6 and its serovariants. Clin Microbiol Rev 2007; 20:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/23\">",
"      Chowdhury NR, Chakraborty S, Ramamurthy T, et al. Molecular evidence of clonal Vibrio parahaemolyticus pandemic strains. Emerg Infect Dis 2000; 6:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/24\">",
"      Bhuiyan NA, Ansaruzzaman M, Kamruzzaman M, et al. Prevalence of the pandemic genotype of Vibrio parahaemolyticus in Dhaka, Bangladesh, and significance of its distribution across different serotypes. J Clin Microbiol 2002; 40:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/25\">",
"      Yeung PS, Hayes MC, DePaola A, et al. Comparative phenotypic, molecular, and virulence characterization of Vibrio parahaemolyticus O3:K6 isolates. Appl Environ Microbiol 2002; 68:2901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/26\">",
"      Han H, Wong HC, Kan B, et al. Genome plasticity of Vibrio parahaemolyticus: microevolution of the 'pandemic group'. BMC Genomics 2008; 9:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/27\">",
"      DePaola A, Ulaszek J, Kaysner CA, et al. Molecular, serological, and virulence characteristics of Vibrio parahaemolyticus isolated from environmental, food, and clinical sources in North America and Asia. Appl Environ Microbiol 2003; 69:3999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/28\">",
"      Ansaruzzaman M, Lucas M, Deen JL, et al. Pandemic serovars (O3:K6 and O4:K68) of Vibrio parahaemolyticus associated with diarrhea in Mozambique: spread of the pandemic into the African continent. J Clin Microbiol 2005; 43:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/29\">",
"      Martinez-Urtaza J, Simental L, Velasco D, et al. Pandemic Vibrio parahaemolyticus O3:K6, Europe. Emerg Infect Dis 2005; 11:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/30\">",
"      Gonz&aacute;lez-Escalona N, Cachicas V, Acevedo C, et al. Vibrio parahaemolyticus diarrhea, Chile, 1998 and 2004. Emerg Infect Dis 2005; 11:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/31\">",
"      Martinez-Urtaza J, Huapaya B, Gavilan RG, et al. Emergence of Asiatic Vibrio diseases in South America in phase with El Ni&ntilde;o. Epidemiology 2008; 19:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/32\">",
"      Newton A, Kendall M, Vugia DJ, et al. Increasing rates of vibriosis in the United States, 1996-2010: review of surveillance data from 2 systems. Clin Infect Dis 2012; 54 Suppl 5:S391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/33\">",
"      Garc&iacute;a K, Torres R, Uribe P, et al. Dynamics of clinical and environmental Vibrio parahaemolyticus strains during seafood-related summer diarrhea outbreaks in southern Chile. Appl Environ Microbiol 2009; 75:7482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/34\">",
"      Bean NH, Maloney EK, Potter ME, et al. Crayfish: a newly recognized vehicle for vibrio infections. Epidemiol Infect 1998; 121:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/35\">",
"      Daniels NA, MacKinnon L, Bishop R, et al. Vibrio parahaemolyticus infections in the United States, 1973-1998. J Infect Dis 2000; 181:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/36\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of Vibrio parahaemolyticus infection associated with eating raw oysters and clams harvested from Long Island Sound--Connecticut, New Jersey, and New York, 1998. MMWR Morb Mortal Wkly Rep 1999; 48:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/37\">",
"      Dechet AM, Yu PA, Koram N, Painter J. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006. Clin Infect Dis 2008; 46:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/38\">",
"      Yoder JS, Hlavsa MC, Craun GF, et al. Surveillance for waterborne disease and outbreaks associated with recreational water use and other aquatic facility-associated health events--United States, 2005-2006. MMWR Surveill Summ 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Vibrio illnesses after Hurricane Katrina--multiple states, August-September 2005. MMWR Morb Mortal Wkly Rep 2005; 54:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/40\">",
"      Hughes JM, Boyce JM, Aleem AR, et al. Vibrio parahaemolyticus enterocolitis in Bangladesh: report of an outbreak. Am J Trop Med Hyg 1978; 27:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/41\">",
"      Bolen JL, Zamiska SA, Greenough WB 3rd. Clinical features in enteritis due to Vibrio parahemolyticus. Am J Med 1974; 57:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/42\">",
"      Bej AK, Patterson DP, Brasher CW, et al. Detection of total and hemolysin-producing Vibrio parahaemolyticus in shellfish using multiplex PCR amplification of tl, tdh and trh. J Microbiol Methods 1999; 36:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27878/abstract/43\">",
"      Depaola A, Jones JL, Noe KE, et al. Survey of postharvest-processed oysters in the United States for levels of Vibrio vulnificus and Vibrio parahaemolyticus. J Food Prot 2009; 72:2110.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3127 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-D3B5B19E3F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27878=[""].join("\n");
var outline_f27_14_27878=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12051994\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12051994\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3127\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3127|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/4/43086\" title=\"table 1\">",
"      Clinical syndromes by Vibrio species",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18502?source=related_link\">",
"      Infections due to non-O1/O139 Vibrio cholerae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=related_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=related_link\">",
"      Vibrio vulnificus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_14_27879="Sonographic characteristics of parathyroid adenomas";
var content_f27_14_27879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sonographic characteristics of parathyroid adenomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 575px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound views of parathyroid adenomas.",
"    <br>",
"     (A) Sagittal image of the upper pole of the right lobe of the thyroid gland, demonstrating a hypoechoic parathyroid adenoma posterior to the thyroid parenchyma.",
"     <br>",
"      (B) Sagittal image of the lower pole of the lower pole of the left lobe of the thyroid gland with an adjacent hypoechoic parathyroid adenoma measuring 9 mm in greatest dimension.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Mulholland, MW, Maier, RV. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27879=[""].join("\n");
var outline_f27_14_27879=null;
var title_f27_14_27880="Prevention of bronchopulmonary dysplasia";
var content_f27_14_27880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of bronchopulmonary dysplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/14/27880/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27880/contributors\">",
"     James M Adams, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27880/contributors\">",
"     Ann R Stark, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/14/27880/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27880/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27880/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/14/27880/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27880/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/14/27880/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchopulmonary dysplasia (BPD), also known as neonatal chronic lung disease (CLD), is an important cause of respiratory illness in preterm newborns. Factors implicated in the pathogenesis of BPD include prematurity, and inflammation caused by mechanical injury, oxygen toxicity, and infection. Many strategies have been attempted to prevent BPD. Success has been limited, in part, because the etiology of the disorder is multifactorial and multiple interventions are needed.",
"   </p>",
"   <p>",
"    Potential strategies to prevent BPD are reviewed here. The pathogenesis, clinical features, management, and prognosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15753?source=see_link\">",
"     \"Management of bronchopulmonary dysplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25398?source=see_link\">",
"     \"Outcome of infants with bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different degrees of prematurity are defined by gestational age (GA), which is calculated from the first day of the mother's last period, or birthweight (BW). Data on BPD is often based upon the following classification of preterm infants categorized by birthweight as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low birth weight (LBW) - BW less than 2500 g",
"     </li>",
"     <li>",
"      Very low birth weight (VLBW) - BW less than 1500 g",
"     </li>",
"     <li>",
"      Extremely low birth weight (ELBW) - BW less than 1000 g",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These terms are used throughout this discussion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following interventions are generally used in combination to improve outcome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduce the risk of BPD in premature infants:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antenatal glucocorticoid therapy",
"     </li>",
"     <li>",
"      Fluid restriction",
"     </li>",
"     <li>",
"      Protective ventilatory strategies that minimize barotrauma or volutrauma in infants who require respiratory support",
"     </li>",
"     <li>",
"      Caffeine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other potential interventions include vitamin A supplementation and late surfactant replacement. Measures that are not currently recommended include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superoxide dismutase because current investigational data suggest it does not reduce the risk of BPD",
"     </li>",
"     <li>",
"      Routine use of postnatal glucocorticoid therapy because of concerns that its known adverse effects outweigh its potential benefit.",
"     </li>",
"     <li>",
"      Inhaled nitric oxide as available evidence does not support its use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following sections discuss each of the above interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Antenatal glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antenatal corticosteroids given to women at risk for preterm delivery decrease the neonatal risk of respiratory distress syndrome (RDS), intraventricular hemorrhage, and mortality. In particular, trials have consistently confirmed a significant reduction in the frequency of RDS among neonates who received antenatal glucocorticoid therapy resulting in less need for mechanical ventilation and oxygen supplementation, which are risk factors for BPD. Thus, antenatal glucocorticoid therapy should be given to any pregnant woman from 24 to 34 weeks of gestation with intact membranes who is at risk for preterm delivery within the next seven days (",
"    <a class=\"graphic graphic_table graphicRef76628 \" href=\"UTD.htm?5/62/6124\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, antenatal glucocorticoid therapy has not decreased the incidence of BPD because the increased survival rate associated with its use results in more infants at-risk for BPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Postnatal glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of postnatal systemic corticosteroids reduces the rate of BPD and improves short-term lung function in infants with established BPD. However, the potential benefits of systemic glucocorticoids, particularly",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , appear to be outweighed by its known short-term and long-term adverse effects, including cerebral palsy. As a result, we follow the recommendation of the American Academy of Pediatrics and the Canadian Paediatric Society, and do",
"    <strong>",
"     NOT",
"    </strong>",
"    routinely administer postnatal glucocorticoids to VLBW infants to prevent or treat BPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3353?source=see_link&amp;anchor=H3#H3\">",
"     \"Postnatal use of glucocorticoids in bronchopulmonary dysplasia\", section on 'Systemic steroids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence that inhaled glucocorticoid prevents BPD in at-risk preterm infants. As a result, we follow the recommendation of the American Academy of Pediatrics and the Canadian Paediatric Society, and do",
"    <strong>",
"     NOT",
"    </strong>",
"    administer inhaled glucocorticoids to at-risk preterm infants to prevent BPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3353?source=see_link&amp;anchor=H12#H12\">",
"     \"Postnatal use of glucocorticoids in bronchopulmonary dysplasia\", section on 'Inhaled glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surfactant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous surfactant therapy is effective in the prevention and treatment of RDS resulting in less need for mechanical ventilation and oxygen supplementation (risk factors for BPD). However, similar to antenatal glucocorticoid therapy, surfactant has not reduced the incidence of BPD because of the increased survival rate of VLBW infants who are at-risk for BPD. The use of surfactant to prevent and treat RDS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link&amp;anchor=H23056094#H23056094\">",
"     \"Prevention and treatment of respiratory distress syndrome in preterm infants\", section on 'Surfactant therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fluid restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive fluid balance defined as a lack of postnatal weight loss during the immediate postnatal period has been proposed as a predisposing risk factor for BPD. This hypothesis is supported by a retrospective report of premature infants (BW between 401 and 1000 g) from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network study that found infants who either died or developed BPD had a higher fluid intake and a lower weight loss during the first 10 days of life compared to those who survived without BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, small trials of fluid restriction have not shown a consistent effect on the development of BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/2\">",
"     2",
"    </a>",
"    ]. In one study, 168 ventilated infants (gestational age 23 to 33 weeks) were randomly assigned to receive routine fluid volumes (60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    on the first day, progressing to 150",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    on the seventh day) or 80 percent of routine volume [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/2\">",
"     2",
"    </a>",
"    ]. Similar proportions in each group had BPD (26 versus 25 percent) and survived without oxygen treatment at 36 weeks postmenstrual age (PMA) (58 versus 52 percent). However, significantly fewer restricted infants received postnatal corticosteroid treatment (19 versus 43 percent), suggesting that their clinicians may have considered they had less severe disease than controls. In addition, colloid infusion increased the duration of oxygen requirement.",
"   </p>",
"   <p>",
"    Fluid restriction may reduce pulmonary edema and potentially minimize lung injury that contributes to BPD. This was suggested by a trial of infants &le;1750 g who were randomly assigned to restricted or routine fluid intake for four weeks after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/3\">",
"     3",
"    </a>",
"    ]. At four weeks, significantly more infants in the restricted group survived without radiographic signs of BPD.",
"   </p>",
"   <p>",
"    There are no data to support the use of diuretic therapy in maintaining a neutral or negative fluid balance. In our practice, diuretic therapy is used in chronically ventilator-dependent infants with moderate to severe lung function impairment after a trial of fluid restriction (130 to 150",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    has failed to significantly improve their pulmonary status.",
"   </p>",
"   <p>",
"    Modest fluid restriction may also reduce the risk of developing a symptomatic patent ductus arteriosus (PDA) that increases left-to-right shunting and pulmonary circulation, which raises the risk of BPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15145?source=see_link&amp;anchor=H10685880#H10685880\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\", section on 'Bronchopulmonary dysplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the mixed results regarding the effect of fluid restriction on clinical outcome, it seems prudent to minimize fluid intake as much as possible. This strategy results in avoidance of excessive pulmonary fluid and the development of pulmonary edema or a symptomatic PDA that may contribute to the pathogenesis of BPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Protective ventilation strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical ventilation has been a lifesaving intervention in the care of premature infants with premature lung development. However, mechanical ventilation causes tissue injury and inflammation that contribute to BPD. As a result, the following strategies have been developed as attempts to reduce or avoid the trauma of mechanical ventilation, in the hopes of decreasing BPD. However, it remains uncertain what is the optimal approach for mechanical ventilation to reduce the incidence of BPD.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minimal ventilation with permissive hypercapnia",
"     </li>",
"     <li>",
"      High frequency oscillatory ventilation",
"     </li>",
"     <li>",
"      Early application of continuous positive airway pressure (CPAP)",
"     </li>",
"     <li>",
"      Noninvasive mechanical ventilation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Minimal ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical ventilation with high tidal volumes results in mechanical injury to the lung, and the use of small tidal volumes may protect the lung from mechanical injury. Because it is difficult to measure delivered tidal volume in infants, neonatal randomized trials comparing low versus high tidal volume ventilation have not been performed. Permissive hypercapnia (defined as PCO2 between 50 and 55 mmHg) is used as a clinical surrogate for low tidal volume ventilation in studies of preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of minimal ventilation with permissive hypercapnia has not been definitively demonstrated in preterm infants at-risk for BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In one trial, ELBW infants requiring mechanical ventilation before 12 hours of age were randomly assigned to minimal ventilation (target PCO2 &gt;52 mmHg) or routine ventilation (PCO2 &lt;48 mm Hg), as well as a course of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/4\">",
"     4",
"    </a>",
"    ]. The trial was stopped after enrollment of 220 infants because of excess adverse events in infants treated with dexamethasone. Although, there was no difference between ventilator groups in the combined primary outcome of death or BPD at 36 weeks PMA, the proportion of infants requiring mechanical ventilation was less in the minimal versus routine ventilation groups (1 versus 16 percent). Major morbidities and long-term outcome were comparable in both treatment groups.",
"   </p>",
"   <p>",
"    The lack of difference in the combined outcome of death or BPD between the minimal and routine ventilation groups may be due, in part, to an insufficient sample size. Another reason may be that the PCO2 targeted values were not accurate clinical surrogates for low and high tidal volumes between the two groups. PCO2 differences between the groups were small. Because ventilated infants continued to breathe spontaneously, the measured PCO2 reflected both the selected airway pressure (which determines the tidal volume) and ventilator rate, and the infant's own ventilation. Spontaneous breathing may have resulted in only modest increase in PCO2 in the minimal ventilation group and minimized the difference between groups resulting in the negative result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Volume targeted ventilation (VTV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume targeted techniques for neonatal ventilation include volume controlled ventilation and volume guarantee. Volume guarantee, combined with synchronized intermittent mandatory ventilation (SIMV) has been reported to decrease the number of high volume mechanical breaths and the peak inspiratory pressure of triggered ventilator breaths. The impact of volume targeted ventilation strategies are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4729?source=see_link&amp;anchor=H9#H9\">",
"     \"Mechanical ventilation in neonates\", section on 'Volume-targeted ventilation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    At our centers, the use of VTV is considered for a select population of premature infants who are treated with surfactant and are at-risk for BPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4729?source=see_link&amp;anchor=H13#H13\">",
"     \"Mechanical ventilation in neonates\", section on 'Our approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     High frequency oscillatory ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;High frequency oscillatory ventilation (HFOV), a technique of rapid ventilation with very small tidal volumes, reduces lung injury in animal models compared to conventional positive pressure ventilation. However, nearly all trials comparing HFOV to conventional ventilation performed in preterm infants since surfactant replacement therapy has been available show no effect on the rate of BPD. Despite the lack of data, a trial of HFOV, as rescue ventilation to minimize volutrauma, often is used in infants with persistent, severe respiratory failure unresponsive to conventional mechanical ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4729?source=see_link&amp;anchor=H10#H10\">",
"     \"Mechanical ventilation in neonates\", section on 'High frequency ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Continuous positive airway pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In preterm infants without respiratory failure, a possibly preferred alternative to mechanical ventilation is continuous positive airway pressure (CPAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/7\">",
"     7",
"    </a>",
"    ]. Early application of CPAP in preterm infants at-risk for or with RDS reduces the need for intubation and mechanical ventilation and is discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link&amp;anchor=H23056129#H23056129\">",
"     \"Prevention and treatment of respiratory distress syndrome in preterm infants\", section on 'Continuous positive airway pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Noninvasive mechanical ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal nasal intermittent positive pressure ventilation (NIPPV) provides noninvasive respiratory support to preterm infants who otherwise would require endotracheal intubation and ventilation. It is an augmentation of continuous positive airway pressure (CPAP), which superimposes inflations set to a peak pressure delivered through nasal prongs or mask.",
"   </p>",
"   <p>",
"    Although limited data suggest that infants treated with NIPPV compared to either intubation or conventional ventilation or CPAP had a lower risk of the combined outcome of death and BPD, the evidence is not conclusive, and some of the preliminary studies have focused only on short-term results during the postextubation period. More data are required to evaluate the efficacy and potential role of this technique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link&amp;anchor=H23056144#H23056144\">",
"     \"Prevention and treatment of respiratory distress syndrome in preterm infants\", section on 'Nasal intermittent positive pressure ventilation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4729?source=see_link&amp;anchor=H12#H12\">",
"     \"Mechanical ventilation in neonates\", section on 'Noninvasive mechanical ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Target pulse oximetry saturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulse oximetry saturation (SpO2) targets greater than 95 percent may result in excess oxygen exposure and hyperoxia in infants receiving supplemental oxygen. For example, VLBW infants maintained at SpO2 values greater than 95 percent are more likely to develop BPD than those maintained at lower saturation values. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=see_link&amp;anchor=H18#H18\">",
"     \"Oxygen monitoring and therapy in the newborn\", section on 'Oxygen target levels'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal range of oxygen saturation, especially for premature infants, is uncertain, and is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=see_link&amp;anchor=H20#H20\">",
"     \"Oxygen monitoring and therapy in the newborn\", section on 'High versus low SpO2 target'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Caffeine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caffeine therapy, in doses used to treat apnea of prematurity, appears to reduce the incidence of BPD. This was illustrated in a multi-center trial that randomly assigned caffeine or placebo to 2006 infants with birth weights between 500 and 1250 g during the first ten days of life, until drug therapy for apnea of prematurity was no longer indicated. Infants who received caffeine compared to controls had a lower incidence of BPD, defined as an oxygen treatment at 36 weeks PMA (36 versus 47 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/8\">",
"     8",
"    </a>",
"    ]. The difference in the incidence of BPD was attributed in part to a shorter period (about one week) of positive pressure support in the caffeine treated patients compared to the controls. Although evaluation of survivors at 18 to 21 months corrected age demonstrated caffeine compared to placebo was associated with a lower incidence of the primary combined outcome of death or neurodevelopmental disability (40.2 versus 46.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/9\">",
"     9",
"    </a>",
"    ], there was no difference between the two groups in death or survival with severe disability (defined differently than the main trial) at follow-up at five years corrected age (21.1 versus 24.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the reduced-risk of BPD, we begin caffeine therapy within the first 10 days of age in infants with birth weight &le; 1250 g. The dosing of caffeine is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of apnea of prematurity\", section on 'Caffeine administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16301699\">",
"    <span class=\"h2\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is well established that inhaled nitric oxide (iNO) provides benefit in the treatment of term or late preterm infants with persistent pulmonary hypertension. In addition, animal studies demonstrated that iNO reduced lung inflammation, improved surfactant function, attenuated hyperoxic lung injury, and promoted lung growth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link&amp;anchor=H23#H23\">",
"     \"Persistent pulmonary hypertension of the newborn\", section on 'Inhaled nitric oxide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of randomized masked controlled clinical trials have been conducted to evaluate the safety and efficacy of iNO to prevent BPD and reduce mortality in preterm infants with respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. These trials have significant differences in study design (eg, dose, duration, early versus late administration of iNO, and severity of illness).",
"   </p>",
"   <p>",
"    Despite these variations in study design, systematic reviews have found no significant benefit of iNO over placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. A 2011 systematic review, which included 14 trials with 7 follow-up studies and one observational study, found no difference in mortality (RR 0.97, 95% CI 0.82-1.15) or the incidence of BPD (RR 0.93, 95% CI 0.86-1.003) between patients who received iNO compared with the control groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/22\">",
"     22",
"    </a>",
"    ]. There was a small difference of improved composite outcome of death or BPD in the iNO group compared with controls (RR 0.93, 95% CI 0.87-0.99). However, there was heterogeneity among the studies as eight reported no difference between the groups, whereas three showed a significant benefit of iNO over placebo. In addition, there were no differences in the incidence of adverse effects or developmental outcome.",
"   </p>",
"   <p>",
"    Because of the heterogeneity of the clinical trials, an additional meta-analysis, which collected and reanalyzed raw data from each randomly assigned patient, was performed. This analysis, which included 12 of the above trials, also found no difference between patients who received iNO compared with control patients in mortality or risk of BPD (59 versus 61 percent), or severe neurologic findings on imaging (25 versus 23 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/23\">",
"     23",
"    </a>",
"    ]. Study protocols varied with differences in starting doses, and duration, timing and indication for treatment. In separate subgroup analyses, there was no beneficial effect of iNO in patients based on birth weight or severity of illness, or duration of therapy. In one analysis, a starting dose of iNO&gt;5 ppm compared with controls was associated with a decrease in the risk of the composite outcome of death or BPD, which was not seen in trials starting with lower doses (ie, &le;5 ppm). However, the authors of the meta-analysis suggest that further study is warranted because of differences in the clinical designs of the included trials in this sub-group analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16301713\">",
"    <span class=\"h3\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the currently available data, we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend the routine administration of iNO to preterm infants with RDS. Until an effective regimen is determined that demonstrates a substantial benefit of iNO justifying its cost, iNO administration should be limited to clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/25\">",
"     25",
"    </a>",
"    ]. This approach is consistent with the conclusions of an expert panel convened by the National Institute of Health that did not support the use of iNO in the treatment of preterm infants below 34 weeks gestation who require respiratory support [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other interventions, which have not been universally adopted but appear to be effective in preventing BPD, include vitamin A, and, to a lesser extent, late administration of surfactant. Although superoxide dismutase had been proposed as a measure to prevent BPD, currently available data suggest that it does not reduce the risk of BPD, and it is used only as an investigational therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Vitamin A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extremely preterm infants may have vitamin A deficiency, which may promote the development of BPD. Possible mechanisms include impaired lung healing, increased squamous cell metaplasia, reduced alveolar number, increased susceptibility to infection, and increased loss of cilia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supplementation with vitamin A appears to reduce the risk of BPD in susceptible infants. A meta-analysis of seven randomized trials showed systemic supplementation of vitamin A in sufficient quantities to establish normal serum retinol concentrations reduced the incidence of BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/28\">",
"     28",
"    </a>",
"    ]. In the largest of these trials, 807 ELBW infants who required at 24 hours of age either mechanical ventilation or supplemental oxygen were randomly assigned to receive 5000 IU vitamin A intramuscularly three times per week for four weeks or a sham injection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/27\">",
"     27",
"    </a>",
"    ]. The combined outcome of death or BPD (oxygen treatment at 36 weeks PMA) was lower in the vitamin A group compared to control (55 versus 62 percent). No clinical or biochemical evidence of vitamin A toxicity was detected. In a subsequent study of the original cohort, there were no differences in the rate of hospitalizations or pulmonary problems after discharge from the nursery, mortality or neurodevelopment impairment between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our center, we administer supplemental vitamin A (5000 IU intramuscularly three times per week for four weeks) to ELBW infants who require ventilatory support within 24 hours after birth. Since the incidence of BPD varies among neonatal intensive care units (NICUs), the decision to use vitamin A supplementation may depend upon a balance of factors, such as the local incidence, the value of a modest decrease in BPD, and the need for repeated intramuscular injections [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Late surfactant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late deficiency of postnatal surfactant production or surfactant dysfunction may play a role in the pathogenesis of BPD because it may be associated with episodes of respiratory deterioration in ventilator-dependent preterm infants. A small pilot trial reported trends towards lower oxygen requirements and risk of mortality and BPD in ventilator-dependent infants (BW range 600 to 900 g) treated with surfactant between 3 and 10 days of age compared to those who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/31\">",
"     31",
"    </a>",
"    ]. Larger trials are currently in progress and are needed to determine whether or not there is a role for late surfactant replacement therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Superoxide dismutase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm infants may have inadequate antioxidant defense because of nutrient deficiencies or immature enzyme development. Although observational studies had suggested postnatal administration of antioxidants (eg, superoxide dismutase) may protect against oxidant injury, randomized trials found no differences between infants who were randomly assigned superoxide dismutase and those who received placebo in the incidence of BPD at 36 weeks PMA, and in growth or neurodevelopmental status at one year corrected age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Superoxide dismutase remains an investigational drug; we do",
"    <strong>",
"     not",
"    </strong>",
"    routinely administer superoxide dismutase in preterm infants to prevent BPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a summary of the strategies that we use to reduce the incidence of BPD in VLBW infants who are at-risk for developing BPD. The combination of interventions addresses the multiple risk factors implicated in the pathogenesis of BPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\", section on 'Pathogenesis and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antenatal corticosteroids are given to any pregnant woman at 24 to 34 weeks of gestation with intact membranes at high risk for preterm delivery within the next seven days (",
"      <a class=\"graphic graphic_table graphicRef76628 \" href=\"UTD.htm?5/62/6124\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We do",
"      <strong>",
"       NOT",
"      </strong>",
"      routinely administer postnatal systemic or inhaled corticosteroids to prevent BPD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3353?source=see_link\">",
"       \"Postnatal use of glucocorticoids in bronchopulmonary dysplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fluids are adjusted to maintain neutral or slightly negative water balance, and positive water balance is avoided. We also avoid the use of colloid infusions, such as albumin.",
"     </li>",
"     <li>",
"      In our centers, nutritional goals are set to provide adequate caloric intake to promote somatic and lung growth [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27880/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=see_link&amp;anchor=H7279167#H7279167\">",
"       \"Growth management in preterm infants\", section on 'Growth in the NICU'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In active infants without respiratory failure, we use early CPAP. In those who require intubation, we provided early surfactant therapy. In our centers, we do NOT routinely use noninvasive mechanical ventilation as it remains uncertain whether it offers additional benefit over the use of early CPAP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link\">",
"       \"Prevention and treatment of respiratory distress syndrome in preterm infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In infants who require supplemental oxygen, we set an upper limit for target pulse oximetry saturation between 95 and 96 percent or less. Appropriate saturation targets for term babies with congenital heart disease or persistent pulmonary hypertension must be determined individually. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Target pulse oximetry saturation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In preterm infants with respiratory failure, synchronized intermittent ventilation (SIMV) is initiated using low tidal volumes (4 to 6",
"      <span class=\"nowrap\">",
"       ml/kg)",
"      </span>",
"      with permissive hypercapnia either with a conventional time-cycled pressure-limited mode or in VLBW infants (birth weight below 1500 g) volume guarantee. Ventilatory settings are adjusted to maintain pCO2 at targeted values between 50 and 55 mmHg during the acute respiratory illness (first 10 to 14 days of life), and PCO2 up to 60 mmHg with pH &ge;7.25 in infants who remain ventilator dependent for longer periods. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4729?source=see_link&amp;anchor=H5#H5\">",
"       \"Mechanical ventilation in neonates\", section on 'Conventional ventilation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In infants with persistent, severe respiratory failure despite the use of conventional ventilation, a trial of high frequency oscillatory ventilation is used to minimize volutrauma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4729?source=see_link&amp;anchor=H10#H10\">",
"       \"Mechanical ventilation in neonates\", section on 'High frequency ventilation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We administer caffeine to all infants with BW &lt;1250 g within the first 10 days of life. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Caffeine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In ELBW infants who require mechanical ventilation by 24 hours of age, we administer supplemental vitamin A (5000 IU intramuscularly three times per week for four weeks). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Vitamin A'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not use of inhaled nitric oxide to prevent BPD in preterm infants. (See",
"      <a class=\"local\" href=\"#H16301699\">",
"       'Nitric oxide'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/24/32129?source=see_link\">",
"       \"Patient information: Bronchopulmonary dysplasia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a summary of recommendations that we use to reduce the risk of bronchopulmonary dysplasia (BPD) in very low birth weight infants (birth weight &lt;1500 g) who are at risk for BPD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend a course of antenatal corticosteroids be given to any pregnant woman at 24 to 34 weeks of gestation with intact membranes at high risk for preterm delivery within the next seven days (",
"      <a class=\"graphic graphic_table graphicRef76628 \" href=\"UTD.htm?5/62/6124\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"       \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       NOT",
"      </strong>",
"      to routinely administer either postnatal systemic or inhaled glucocorticoids to preterm infants for the prevention of BPD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3353?source=see_link\">",
"       \"Postnatal use of glucocorticoids in bronchopulmonary dysplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the infant is active and breathing spontaneously, we recommend infants with respiratory distress be treated with continuous positive airway pressure (CPAP) rather than mechanical ventilation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If mechanical ventilation is used, we suggest the use of low tidal volumes (4 to 6",
"      <span class=\"nowrap\">",
"       ml/kg)",
"      </span>",
"      with permissive hypercapnia to minimize volutrauma that may contribute to the pathogenesis of BPD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Protective ventilation strategies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link&amp;anchor=H23056122#H23056122\">",
"       \"Prevention and treatment of respiratory distress syndrome in preterm infants\", section on 'Assisted ventilation techniques'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In infants who require supplemental oxygen, we suggest target pulse oximetry saturation be set for values between 90 and 96 percent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Target pulse oximetry saturation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=see_link&amp;anchor=H18#H18\">",
"       \"Oxygen monitoring and therapy in the newborn\", section on 'Oxygen target levels'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend the administration of caffeine therapy to preterm infants with birth weights (BW) &lt;1250 g within the first 10 days of life (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Caffeine'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=see_link&amp;anchor=H17#H17\">",
"       \"Management of apnea of prematurity\", section on 'Other therapies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest supplemental vitamin A therapy (5000 IU intramuscularly three times per week for four weeks) in extremely low birth weight infants (BW &lt;1000 g) who require ventilatory support within 24 hours after birth (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Vitamin A'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In all preterm infants, nutritional goals are set to provide adequate caloric intake to promote somatic and lung growth, and fluid intake is adjusted to maintain neutral or slightly negative water balance. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Fluid restriction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=see_link&amp;anchor=H7279167#H7279167\">",
"       \"Growth management in preterm infants\", section on 'Growth in the NICU'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We do not recommend the use of inhaled nitric oxide to prevent BPD in preterm infants (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/1\">",
"      Oh W, Poindexter BB, Perritt R, et al. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 2005; 147:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/2\">",
"      Kavvadia V, Greenough A, Dimitriou G, Hooper R. Randomised trial of fluid restriction in ventilated very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2000; 83:F91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/3\">",
"      Tammela OK, Lanning FP, Koivisto ME. The relationship of fluid restriction during the 1st month of life to the occurrence and severity of bronchopulmonary dysplasia in low birth weight infants: a 1-year radiological follow up. Eur J Pediatr 1992; 151:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/4\">",
"      Carlo WA, Stark AR, Wright LL, et al. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. J Pediatr 2002; 141:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/5\">",
"      Mariani G, Cifuentes J, Carlo WA. Randomized trial of permissive hypercapnia in preterm infants. Pediatrics 1999; 104:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/6\">",
"      Woodgate PG, Davies MW. Permissive hypercapnia for the prevention of morbidity and mortality in mechanically ventilated newborn infants. Cochrane Database Syst Rev 2001; :CD002061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/7\">",
"      Aly H. Is there a strategy for preventing bronchopulmonary dysplasia? Absence of evidence is not evidence of absence. Pediatrics 2007; 119:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/8\">",
"      Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/9\">",
"      Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007; 357:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/10\">",
"      Schmidt B, Anderson PJ, Doyle LW, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA 2012; 307:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/11\">",
"      Kang JL, Park W, Pack IS, et al. Inhaled nitric oxide attenuates acute lung injury via inhibition of nuclear factor-kappa B and inflammation. J Appl Physiol 2002; 92:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/12\">",
"      Ballard PL, Gonzales LW, Godinez RI, et al. Surfactant composition and function in a primate model of infant chronic lung disease: effects of inhaled nitric oxide. Pediatr Res 2006; 59:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/13\">",
"      Cotton RB, Sundell HW, Zeldin DC, et al. Inhaled nitric oxide attenuates hyperoxic lung injury in lambs. Pediatr Res 2006; 59:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/14\">",
"      McCurnin DC, Pierce RA, Chang LY, et al. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am J Physiol Lung Cell Mol Physiol 2005; 288:L450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/15\">",
"      Tang JR, Markham NE, Lin YJ, et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 2004; 287:L344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/16\">",
"      Schreiber MD, Gin-Mestan K, Marks JD, et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003; 349:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/17\">",
"      Van Meurs KP, Wright LL, Ehrenkranz RA, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005; 353:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/18\">",
"      Kinsella JP, Cutter GR, Walsh WF, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006; 355:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/19\">",
"      Ballard RA, Truog WE, Cnaan A, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/20\">",
"      Mercier JC, Hummler H, Durrmeyer X, et al. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet 2010; 376:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/21\">",
"      Patrianakos-Hoobler AI, Marks JD, Msall ME, et al. Safety and efficacy of inhaled nitric oxide treatment for premature infants with respiratory distress syndrome: follow-up evaluation at early school age. Acta Paediatr 2011; 100:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/22\">",
"      Donohue PK, Gilmore MM, Cristofalo E, et al. Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics 2011; 127:e414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/23\">",
"      Askie LM, Ballard RA, Cutter GR, et al. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Pediatrics 2011; 128:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/24\">",
"      Barrington KJ, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2010; :CD000509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/25\">",
"      Stark AR. Inhaled NO for preterm infants--getting to yes? N Engl J Med 2006; 355:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/26\">",
"      Cole FS, Alleyne C, Barks JD, et al. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics 2011; 127:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/27\">",
"      Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999; 340:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/28\">",
"      Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 2002; :CD000501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/29\">",
"      Ambalavanan N, Tyson JE, Kennedy KA, et al. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics 2005; 115:e249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/30\">",
"      Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 2000; :CD000501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/31\">",
"      Laughon M, Bose C, Moya F, et al. A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia. Pediatrics 2009; 123:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/32\">",
"      Davis JM, Rosenfeld WN, Richter SE, et al. Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics 1997; 100:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/33\">",
"      Davis JM, Parad RB, Michele T, et al. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003; 111:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27880/abstract/34\">",
"      Biniwale MA, Ehrenkranz RA. The role of nutrition in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 2006; 30:200.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4992 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27880=[""].join("\n");
var outline_f27_14_27880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Antenatal glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Postnatal glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surfactant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fluid restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Protective ventilation strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Minimal ventilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Volume targeted ventilation (VTV)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - High frequency oscillatory ventilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Continuous positive airway pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Noninvasive mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Target pulse oximetry saturation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Caffeine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16301699\">",
"      Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16301713\">",
"      - Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Vitamin A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Late surfactant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Superoxide dismutase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4992\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4992|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/62/6124\" title=\"table 1\">",
"      NIH recommendationsfor antenatal steroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=related_link\">",
"      Growth management in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=related_link\">",
"      Management of apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15753?source=related_link\">",
"      Management of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4729?source=related_link\">",
"      Mechanical ventilation in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25398?source=related_link\">",
"      Outcome of infants with bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=related_link\">",
"      Oxygen monitoring and therapy in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15145?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/24/32129?source=related_link\">",
"      Patient information: Bronchopulmonary dysplasia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3353?source=related_link\">",
"      Postnatal use of glucocorticoids in bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=related_link\">",
"      Prevention and treatment of respiratory distress syndrome in preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_14_27881="Growth hormone treatment in children with chronic kidney disease and postrenal transplantation";
var content_f27_14_27881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Growth hormone treatment in children with chronic kidney disease and postrenal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/14/27881/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27881/contributors\">",
"     Burkhard T&ouml;nshoff, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/14/27881/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27881/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/14/27881/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27881/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/14/27881/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth impairment is a common problem in children with chronic kidney disease (CKD) and is associated with significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Several factors may contribute, including inadequate nutrition, metabolic acidosis, renal osteodystrophy, and insensitivity to the action of growth hormone (GH) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/3-7\">",
"     3-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management to prevent and correct growth impairment due to CKD includes supportive measures that correct amenable complications of CKD (eg, poor nutrition and metabolic acidosis) and renal replacement therapy (RRT), particularly renal transplantation. However, despite these interventions, poor growth persists in a significant proportion of children with CKD, including renal allograft recipients. In children who have persistent growth impairment,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    therapy (rhGH) is an effective and well tolerated intervention that improves growth.",
"   </p>",
"   <p>",
"    The use of rhGH in children with CKD, including efficacy, indications, and dosing will be reviewed here. The pathogenesis, risk factors, evaluation, and overall management of growth impairment in children with CKD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36713?source=see_link\">",
"     \"Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17240?source=see_link\">",
"     \"Prevention and management of growth failure in children with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70626147\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70626168\">",
"    <span class=\"h2\">",
"     Z-height score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The growth measurement Z-score for height is a conversion of",
"    <span class=\"nowrap\">",
"     height/length",
"    </span>",
"    that represents the number of standard deviations from the mean height for age. A child with a height Z-score &lt;-1.88 has short stature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=see_link&amp;anchor=H5#H5\">",
"     \"Measurement of growth in children\", section on 'Z-scores'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64686581\">",
"    <span class=\"h2\">",
"     Growth or height velocity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth or height velocity, the change in growth over time, is a more sensitive index of growth than is a single measurement. Current",
"    <span class=\"nowrap\">",
"     height/length",
"    </span>",
"    measures are compared with previous growth points to determine the interval",
"    <span class=\"nowrap\">",
"     growth/height",
"    </span>",
"    velocity (",
"    <a class=\"graphic graphic_figure graphicRef66909 \" href=\"UTD.htm?4/37/4692\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74573 \" href=\"UTD.htm?16/0/16387\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164342890\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental and clinical evidence demonstrate that growth hormone (GH) resistance associated with chronic kidney disease (CKD) can be overcome by supraphysiologic doses of exogenous GH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. The administration of exogenous pharmacologic doses of GH results in increased circulating levels of free insulin-like growth factor-I (IGF-I) as the relative increase in IGF-I production is greater than the increase in inhibitory IGF binding proteins, which raises the rate of longitudinal growth.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a uremic animal model, histologic analyses showed increased growth of the proximal tibia in animals treated with GH [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Limited data from patients with CKD also suggest that GH therapy improved bone metabolism. In a small study of 10 pre-pubertal patients with CKD,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"       recombinant human growth hormone",
"      </a>",
"      (rhGH) therapy administered for one year produced a significant increase in lumbar spine and total body bone mineral content and bone mineral density [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is strong evidence from clinical trials and observational data from large registries that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    (rhGH) therapy improves growth in children with chronic kidney disease (CKD).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660580\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized clinical trials have shown that rhGH stimulates growth in children with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/11,13-16\">",
"     11,13-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was best illustrated in a meta-analysis of clinical trials that included 809 children with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/17\">",
"     17",
"    </a>",
"    ]. In this review, some analyses included patients in all clinical settings for CKD: those who never received renal replacement therapy (RRT), were on dialysis, or had received a renal transplantation. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children who were randomly assigned to rhGH (dose 28 international units",
"      <span class=\"nowrap\">",
"       [IU]/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per week) had a greater increase in mean height velocity (+3.9 cm) than patients who received either no treatment or placebo after one year.",
"     </li>",
"     <li>",
"      There was no evidence of adverse effect on renal function. In six trials of children post-renal transplantation, there was no difference in the risk of acute rejection; however, in one trial, there were more episodes of acute rejection in children who received rhGH.",
"     </li>",
"     <li>",
"      There was no evidence of advanced pubertal growth spurt or bone age associated with rhGH therapy.",
"     </li>",
"     <li>",
"      Data from patients followed until they achieved final height demonstrated an improved mean Z-score for final height for the rhGH group compared with the control group (-1.6 versus -2.1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This review was limited as it only was able to study the effects of growth for a maximum of two years. In addition, the relative small number of patients did not allow for sub-group analysis based on the clinical status (ie, CKD without RRT, CKD with dialysis, or allograft recipient).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660587\">",
"    <span class=\"h2\">",
"     NAPTRCS observational data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of rhGH in promoting growth in all three clinical settings of pediatric CKD has been supported by observational data from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS).",
"   </p>",
"   <p>",
"    A 2007 report based on the NAPRTCS registry demonstrated the extent of use of rhGH therapy and its benefit in all three clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 6505 children with CKD without current or previous RRT, 22 percent received rhGH. Hormonal therapy was associated with catch-up growth in 27 percent of treated patients.",
"     </li>",
"     <li>",
"      Of the 5122 children on dialysis, 33 percent received rhGH. Hormonal therapy was associated with catch-up growth in 11 percent of treated patients.",
"     </li>",
"     <li>",
"      Of the 4478 children who received a renal allograft, 3 percent received rhGH. Hormonal therapy was associated with catch-up growth in 25 percent of treated patients.",
"     </li>",
"     <li>",
"      In all groups, the highest catch-up growth was seen in patients who were prepubertal (defined as Tanner stage 1 or 2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70624823\">",
"    <span class=\"h2\">",
"     Specific populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the use of rhGH is beneficial in children with CKD in all three settings of CKD: without RRT, dialysis, and postrenal transplantation. Although most studies have primarily been comprised of prepubertal children, there is also good evidence to support the use of rhGH in infants. It remains uncertain whether rhGH can significantly improve growth in pubertal children as data in this group of patients are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70624946\">",
"    <span class=\"h3\">",
"     Prepubertal patients",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70624954\">",
"    <span class=\"h4\">",
"     CKD without RRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical trials of children with CKD without RRT, which were included in the meta-analysis discussed above, showed patients who received rhGH therapy had an increased growth velocity compared with controls who received placebo therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Genentech Cooperative Study Group trial of 125 children with CKD (mean age six years), the mean growth rate was increased in the rhGH versus the placebo group in both the first year (10.7 versus 6.5",
"    <span class=\"nowrap\">",
"     cm/year)",
"    </span>",
"    and second year (7.8 versus 5.5",
"    <span class=\"nowrap\">",
"     cm/year)",
"    </span>",
"    of the study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/16\">",
"     16",
"    </a>",
"    ]. Continued treatment for a total of five years showed the maximum increase in height occurred during the first two treatment years; however, changes in mean height Z-scores continued to be greater in the rhGH group in subsequent years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational data from the NAPRTCS CKD registry also show the beneficial effect of rhGH in children with CKD who are not receiving RRT. In a case-control study of patients enrolled in the CKD registry (never underwent dialysis or renal transplantation), patients who were treated with rhGH had a better mean height Z-score than matched control patients who did not receive rhGH (-1.46 versus -2.02) after two years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/20\">",
"     20",
"    </a>",
"    ]. Controls were matched by age, gender, base-line height, and length of time on the registry but the estimated glomerular filtration rate (GFR) of the treated group was less than the control group (37.5 versus 42.3",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ). However, the lower GFR would be expected to reduce the height gain in the rhGH group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70625437\">",
"    <span class=\"h4\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the response to rhGH is reduced compared with that seen in children with CKD that do not require RRT, rhGH still is beneficial in patients undergoing dialysis treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies of children undergoing dialysis reported a mean increase of growth velocity of 2.6 to 3.5",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    during the first year of administration of rhGH over the baseline rate before the initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Although the growth rate decreased in subsequent years, it remained above the baseline rate.",
"   </p>",
"   <p>",
"    In the 2011 NAPRTCS dialysis report, children treated with rhGH compared with untreated patients were more likely to be growth impaired at the initiation of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/26\">",
"     26",
"    </a>",
"    ]. However, after 12 months on dialysis, children who received rhGH had a greater change in height Z-score with the greatest improvement in children less than six years of age.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children less than six years of age, the rhGH group had a mean change in height Z-score of +0.63 versus +0.01 for the untreated group.",
"     </li>",
"     <li>",
"      For children six years and older, the mean height Z-scores were +0.26 versus -0.1 for the rhGH and untreated groups, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70625593\">",
"    <span class=\"h4\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful renal transplantation reverses the uremic milieu and should theoretically permit normal GH secretion and function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/27\">",
"     27",
"    </a>",
"    ]. Persistent growth failure in this setting is primarily a result of reduced graft function and glucocorticoid therapy. If catch-up growth cannot be achieved by an alternate-day glucocorticoid regimen, and if discontinuation of glucocorticoids is not possible because of unstable graft function, rhGH therapy may be initiated, particularly in children with suboptimal graft function (GFR below 50",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ), in whom spontaneous catch-up growth is unlikely to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. rhGH is usually prescribed after the first year, however, as discussed below, infants may also see a marked beneficial effect of rhGH. (See",
"    <a class=\"local\" href=\"#H660666\">",
"     'Infants'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Of note, the use of rhGH in pediatric renal allograft recipients is not approved by European or North American drug regulatory agencies.",
"   </p>",
"   <p>",
"    Exogenous GH reverses the catabolic and growth-depressing effects of glucocorticoids in both experimental and clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/30\">",
"     30",
"    </a>",
"    ]. In particular, rhGH can counteract the interference of pharmacological doses of glucocorticoids with the integrity of the",
"    <span class=\"nowrap\">",
"     GH/insulin-like",
"    </span>",
"    growth factor-I (IGF)-axis.",
"   </p>",
"   <p>",
"    Clinical trials, which were included in the previously mentioned meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/17\">",
"     17",
"    </a>",
"    ], have shown the benefit of rhGH in growth-retarded pediatric renal allograft recipients as illustrated by the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/13,14,31\">",
"     13,14,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a French trial, patients assigned to rhGH therapy had a higher growth velocity than control patients in the first year of the study (7.7 versus 4.6 cm per year) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/13\">",
"       13",
"      </a>",
"      ]. Subsequently, a decrease in growth velocity was noted, with growth of 5.9, 5.5, and 5.2 cm occurring at two, three, and four years, respectively. These data indicate that GH therapy clearly induces catch-up growth, but the effect becomes limited with time.",
"     </li>",
"     <li>",
"      In a second randomized controlled trial of growth-retarded patients enrolled in the NAPRTCS registry, patients assigned to rhGH had a higher mean change in height Z-score than control patients after one year (+0.49 versus -0.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional evidence supporting the benefit of rhGH in growth-retarded renal allograft recipients was provided by a retrospective NAPRTCS study that compared the outcome of 513 pediatric renal allograft recipients who received rhGH with 2263 patients who were not treated with rhGH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/32\">",
"     32",
"    </a>",
"    ]. The rhGH treated group had improved growth with a mean cumulative increase in height of 3.6 cm over five years compared with controls, which resulted in higher mean final adult height Z-scores (-1.8 versus -2.6).",
"   </p>",
"   <p>",
"    Although there had been concerns about a possible link between rhGH and an increase in the risk of acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/13\">",
"     13",
"    </a>",
"    ], subsequent data have shown no association between rhGH and acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/14,17,32\">",
"     14,17,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the above discussion and data, it appears that rhGH is effective and safe for use in growth-retarded pediatric renal allograft recipients despite the lack of approval by European or North American drug regulatory agencies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660666\">",
"    <span class=\"h3\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from observational studies and clinical trials suggests that rhGH may be of the greatest benefit when given to infants with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/11,33,34\">",
"     11,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A sub-analysis of Genentech Cooperative Study Group clinical trial demonstrated that infants and young children (less than 2.5 years of age, mean age 1.4 years) who were randomly assigned to rhGH therapy had greater growth rates in both the first year (14.1 versus 9.3 cm) and second year (8.6 versus 6.9 cm) of the study than patients who receive placebo treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a multicenter trial of infants with a mean age of 12 months and a GFR &le;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , patients assigned to rhGH therapy had a greater similar increase in length compared with controls (14.5 versus 9.5 cm). All patients had adequate nutritional intake and good metabolic control [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that early initiation of rhGH therapy in this phase of rapid growth might reverse or prevent the otherwise common irreversible loss of growth potential in infancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36713?source=see_link&amp;anchor=H750225#H750225\">",
"     \"Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease\", section on 'Infancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pubertal children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the effect of rhGH in pubertal patients with CKD. Assessment of growth is also challenging, as the pubertal growth spurt is usually delayed and shortened in patients with CKD. As a result, an adequate evaluation of the effect of rhGH on pubertal growth requires an analysis of the degree and duration of the entire pubertal growth spurt. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36713?source=see_link&amp;anchor=H750239#H750239\">",
"     \"Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease\", section on 'Puberty'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one report that followed initially prepubertal patients (mean age 10.4 years at start of the study) treated long term with rhGH (mean duration of treatment 5.3 years), total pubertal height gain was similar in control and GH-treated children with renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/35\">",
"     35",
"    </a>",
"    ]. The gain was 65 percent of that observed in normal children because of a shorter (by 1.6 years) pubertal growth spurt.",
"   </p>",
"   <p>",
"    In contrast, a study of growth-retarded pubertal children after transplantation treated with rhGH for two years reported a higher mean gain in height compared with historically matched controls (15.7 versus 5.8 cm) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, an analysis of the Pfizer International Growth (KIGS) database demonstrated catch-up growth in patients with CKD who were either in early (Tanner stage II or III) or late puberty (Tanner stage IV or V) when rhGH therapy was initiated with a cumulative increase in mean height Z-scores of 1.3 and 1.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70626075\">",
"    <span class=\"h2\">",
"     Final adult height",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term results of children with CKD treated for five years indicate a positive effect of rhGH on final height, with frequent attainment of normal height [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/19,35,37\">",
"     19,35,37",
"    </a>",
"    ]. In the previously discussed clinical trial of children with CKD, long-term follow-up showed that the mean final adult height was greater in children who were treated with rhGH for a mean of 5.3 years compared with controls (mean height Z-scores: -1.6 versus -2.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/35\">",
"     35",
"    </a>",
"    ]. In the rhGH group, the majority of patients attained normal adult height (defined as height Z-score &gt;-1.88).",
"   </p>",
"   <p>",
"    The efficacy of rhGH to improve final height is mainly affected by the following factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/23,38\">",
"     23,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The total duration of rhGH therapy.",
"     </li>",
"     <li>",
"      The renal failure treatment modality, as end-stage renal disease treated by dialysis adversely affects the long-term efficacy of rhGH.",
"     </li>",
"     <li>",
"      The initial degree of growth retardation as a predictor of rhGH-associated total height gain, indicating that the efficacy of rhGH therapy appears to depend on the biological \"demand\" for catch-up growth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INITIATION OF rhGH THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170177130\">",
"    <span class=\"h2\">",
"     Goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    (rhGH) therapy in children with chronic kidney disease (CKD) is \"normalization\" of final height. There is some debate concerning how this goal is defined. The therapeutic end point could either be attainment of the patient's individual target height (ie, the 50th percentile of mid-parental height) or of a normal population-related final height (ie, greater than the third percentile or a Z-score &gt;-1.88). Although the former goal is certainly desirable for the individual patient, the latter approach may be economically more acceptable in view of the high cost of rhGH therapy (approximately $30,000 per patient per year). In our practice, the minimal therapeutic goal is a height greater than the third percentile of the general population.",
"   </p>",
"   <p>",
"    It is important to monitor the growth of all children with CKD. When there is a reduction of growth velocity below normal values based on age and gender, an evaluation should be performed to determine to identify and correct any amenable risk factors that contribute to growth impairment, such as inadequate nutrition or metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36713?source=see_link&amp;anchor=H85210702#H85210702\">",
"     \"Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease\", section on 'Further evaluation to identify underlying risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17240?source=see_link&amp;anchor=H359697767#H359697767\">",
"     \"Prevention and management of growth failure in children with chronic kidney disease\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170176797\">",
"    <span class=\"h2\">",
"     Timing and indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of initiation of rhGH is based on optimizing the response to therapy when the indications for therapy are met. Data from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) and clinical trials have demonstrated that there is often a delay in initiation of rhGH and children who were already growth-retarded (Z-height score &lt;-1.88) before rhGH is started. Even with rhGH therapy, some of these patients did not have sufficient catch-up growth to obtain normal population-related final height. As a result, early initiation of therapy is advocated for patients who meet the criteria for rhGH therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H162284220\">",
"    <span class=\"h3\">",
"     Predictors for growth response to rhGH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first and second year of treatment, age, glomerular filtration rate, target height (ie, parental height), and prior growth rates are independent predictors of the response to rhGH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/23,38\">",
"     23,38",
"    </a>",
"    ]. Height velocity negatively correlates with increasing age and positively correlates higher renal function and target height. Factors that positively impact final adult stature include Z-height score at initiation of therapy and duration of rhGH therapy, and those with adverse effects include increasing time on dialysis, delayed puberty, and the age at the start of rhGH.",
"   </p>",
"   <p>",
"    These data suggest that earlier intervention at a younger age (before six years of age) and early in the course of the renal failure leads to a more robust response to rhGH and is more likely to result in achieving the goal of a normal final height. In particular, the use of rhGH appears to be most beneficial in infants who are most likely to achieve successful catch-up growth. (See",
"    <a class=\"local\" href=\"#H660666\">",
"     'Infants'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170177383\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for initiation of rhGH therapy in children with CKD are based on limited data and clinical experience. An algorithm was developed by a consensus group of pediatric nephrologists to target the population of children with CKD who would most benefit from rhGH therapy. The following indications were proposed for initiation of therapy, which are consistent to the approach used in our center [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All other amenable factors that contribute to growth impairment have been adequately addressed. These include insufficient nutrition, metabolic acidosis, fluid and electrolyte abnormalities, anemia, and renal osteodystrophy. This is in agreement with the National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative",
"      <span class=\"nowrap\">",
"       (K/DOQI)",
"      </span>",
"      pediatric nutrition guidelines that recommend correction of existing nutritional deficiencies and metabolic abnormalities prior to consideration of rhGH therapy for growth failure [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/39\">",
"       39",
"      </a>",
"      ]. Management of these factors is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17240?source=see_link&amp;anchor=H359697775#H359697775\">",
"       \"Prevention and management of growth failure in children with chronic kidney disease\", section on 'Supportive measures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Estimated glomerular filtration rate is less than 75",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      .",
"     </li>",
"     <li>",
"      There is evidence of growth impairment; the mean Z-score for growth velocity &lt;-2 (",
"      <a class=\"graphic graphic_figure graphicRef70382 \" href=\"UTD.htm?6/6/6253\">",
"       figure 3",
"      </a>",
"      )",
"      <strong>",
"       or",
"      </strong>",
"      mean Z-score for height based on age and gender &lt;-1.88. The following calculators can be used to determine the Z-score for height for boys, girls, and infants (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?21/47/22262?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?22/7/22646?source=see_link\">",
"       calculator 2",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?33/34/34339?source=see_link\">",
"       calculator 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36713?source=see_link&amp;anchor=H85210653#H85210653\">",
"       \"Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with active malignancies should be excluded from rhGH therapy.",
"     </li>",
"     <li>",
"      Baseline assessments should be performed that will be used in monitoring rhGH response and potential adverse effects. These include laboratory testing (ie, glucose, serum creatinine, calcium, phosphorus, and parathyroid hormone), funduscopic examination, bone age, and determining pubertal status (ie, Tanner stage).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dose of rhGH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended dose of rhGH currently used in Europe and the United States for children with CKD is 0.045 to 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight per day, which corresponds to approximately a daily dose of 4 international units (IU) per m",
"    <sup>",
"     2",
"    </sup>",
"    body surface area. This is given daily by subcutaneous injection. Although data are limited, the previously discussed meta-analysis showed that this dose (defined as a cumulative weekly amount of 28",
"    <span class=\"nowrap\">",
"     IU/week",
"    </span>",
"    per m",
"    <sup>",
"     2",
"    </sup>",
"    body surface area in the systematic review) resulted in a higher growth velocity than a lower dose of 14",
"    <span class=\"nowrap\">",
"     IU/week",
"    </span>",
"    per m",
"    <sup>",
"     2",
"    </sup>",
"    body surface area (mean difference of 1.18 cm per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amount of rhGH given to children with CKD is greater than what is normally given to GH-deficient children. This is consistent with the current understanding that CKD causes GH resistance; as a result, pharmacologic rather than replacement dosing is required in treating children with CKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Frequency and mode of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with CKD, daily administration of rhGH is more effective in stimulating growth than injections given three times weekly. However, subcutaneous injection of rhGH is not well accepted by some children. As a result, in children undergoing peritoneal dialysis, rhGH is administrated by installing it into the dialysis fluid, analogous to insulin treatment in diabetic patients. Preliminary data indicate adequate absorption of rhGH via the intraperitoneal route [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/40\">",
"     40",
"    </a>",
"    ]. However, the growth-promoting efficacy of intraperitoneal GH appears to be less consistent than that observed with subcutaneous rhGH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, intraperitoneal instillation of rhGH may increase the risk of peritonitis episodes. Because of these uncertainties, the subcutaneous injection remains the preferred route of administration in children undergoing peritoneal dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170177771\">",
"    <span class=\"h1\">",
"     MONITORING RESPONSE AND FOR ADVERSE EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1446970\">",
"    <span class=\"h2\">",
"     Response to rhGH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing monitoring evaluates the response to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    (rhGH) and detects any potential adverse effects. An adequate growth response is defined as a growth velocity that is greater than 2",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    over the baseline prior to rhGH therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Every three to four months:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Assess growth with measurements of height, weight, and in children younger than three years of age, occipitofrontal circumference, and calculate growth velocity and Z-score for height. If growth velocity decreases, readjustment of the dose might be needed with an increase in weight.",
"     </li>",
"     <li>",
"      Nutritional status",
"     </li>",
"     <li>",
"      Funduscopic examination",
"     </li>",
"     <li>",
"      Pubertal stage",
"     </li>",
"     <li>",
"      Laboratory tests including serum glucose, electrolytes, creatinine, calcium, phosphorus, and parathyroid hormone level",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Yearly: Bone age",
"     </li>",
"     <li>",
"      If symptomatic, hip and knee radiographics",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1446977\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged rhGH therapy does not appear to be associated with any major adverse effects as illustrated by the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/17,42\">",
"     17,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the previously mentioned systematic review, although the number of adverse events was small, the frequency of side effects was similar between the rhGH and control groups [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/17\">",
"       17",
"      </a>",
"      ]. In particular, there were no differences in the risk of kidney function deterioration, lipid profile abnormalities, glucose intolerance, or diabetes mellitus, and in pediatric allograft recipients, the incidence of acute rejection.",
"     </li>",
"     <li>",
"      In a study from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry, the frequency of GH-related adverse events over a 6.5-year period was evaluated in 2333 patients who had current or prior use of rhGH therapy compared with 8533 patients who never received rhGH [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/42\">",
"       42",
"      </a>",
"      ]. There were no differences between the two groups in the incidence of malignancy, slipped capital femoral epiphysis, avascular necrosis, glucose intolerance, pancreatitis, progressive deterioration of renal function, acute allograft rejection, or fluid retention. There was also no significant increase in the incidence of benign intracranial hypertension.",
"     </li>",
"     <li>",
"      In a subsequent study from NAPRTCS, retrospective data demonstrated there was no increased risk of post-transplant lymphoproliferative disease in children who received rhGH during dialysis or post-transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, overall data in all children treated with rhGH suggest that there may be a slightly higher risk of developing idiopathic intracranial hypertension (pseudotumor cerebri), slipped capital femoral epiphysis, and worsening of existing scoliosis. Whether these are true side effects of rhGH itself or related to rapid growth due to rhGH is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of growth hormone deficiency in children\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the above reports of children with chronic kidney disease (CKD), the overall number of adverse events is small, and it is possible that rhGH could be associated with a small increased incidence of adverse effects. However, if there is such a risk, it does not appear to be significant and should not limit the use of rhGH in children who might benefit.",
"   </p>",
"   <p>",
"    Nevertheless, we suggest the following follow-up care of patients with CKD treated long term with rhGH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucose metabolism &ndash; Although rhGH therapy does not alter glucose tolerance in the vast majority of patients, there are two reported individual cases of the development of diabetes mellitus in children with CKD that are temporally related to the initiation of rhGH therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. In both cases, diabetes mellitus was reversible after discontinuation of rhGH therapy. In the NAPRTCS report, eight patients in the control group and",
"      <strong>",
"       no",
"      </strong>",
"      patients in the rhGH developed diabetes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on this limited data, we suggest monitoring of glucose homeostasis, particularly in those patients with additional risk factors, such as concomitant glucocorticoid treatment and familial type 2 diabetes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal function &ndash; The available clinical data indicate that rhGH therapy does",
"      <strong>",
"       not",
"      </strong>",
"      accelerate the loss of residual renal function in children with preterminal CKD [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/16,17,19,42,46\">",
"       16,17,19,42,46",
"      </a>",
"      ]. However, because increases in the plasma creatinine concentration have been observed in individual patients, renal function (serum creatinine) should be monitored, and rhGH therapy should be reconsidered if there is an otherwise unexplained decrease in renal function.",
"     </li>",
"     <li>",
"      Benign intracranial hypertension &ndash; It is uncertain whether pediatric patients treated with rhGH are at increased risk for benign intracranial hypertension. In one large observational study of 1670 children with a variety of renal disease, 15 cases (0.9 percent) of intracranial hypertension were reported [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/47\">",
"       47",
"      </a>",
"      ]. However, all of the 15 children were using other medications which could predispose them to intracranial hypertension. In the systematic review, there was report of one patient each in the rhGH treatment and control groups [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/17\">",
"       17",
"      </a>",
"      ] and in the NAPRTCS study, there was not a difference in the risk of intracranial hypertension between the two groups (0.2 versus 0.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these results, we suggest that follow-up care include routine funduscopic examination to detect any change in optic disc suggestive of intracranial hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link&amp;anchor=H8#H8\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\", section on 'Papilledema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Orthopedic complications &ndash; There is not an associated deterioration of renal osteodystrophy, but rapid growth acceleration may contribute to an increased risk of slipped capital femoral epiphysis. As a result, it is advisable to obtain bone radiographs prior to initiating rhGH and to repeat the studies if symptoms occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=see_link\">",
"       \"Slipped capital femoral epiphysis (SCFE)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170177779\">",
"    <span class=\"h2\">",
"     Failure of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who do not adequately respond to rhGH therapy (ie, growth velocity is less than 2",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    over the baseline prior to rhGH therapy), the following evaluation should be performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess patient compliance.",
"     </li>",
"     <li>",
"      Assess if the weight-based rhGH dose is correct, and if necessary, readjust the dose.",
"     </li>",
"     <li>",
"      Assess whether other nutritional or metabolic factors for poor growth are present, and if so, initiate a corrective treatment plan.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with persistent poor growth despite correction of these issues may require referral to a pediatric endocrinologist for further evaluation of other possible causes for inadequate growth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doubling the dose appears to be a reasonable therapeutic approach in patients who fail to respond to one year of the initial rhGH regimen. We have observed individual patients in whom such an increase in dose induced sustained catch-up growth over time [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/41\">",
"     41",
"    </a>",
"    ]. However, this procedure may present hazards because a higher dose increases the potential risk of side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of rhGH remains uncertain, although clinical studies have shown that the growth response is greatest in the first two years of therapy, growth velocity is persistently greater than baseline in years three through five of therapy. Dosing needs to be readjusted every three to four months based on the weight of the patient.",
"   </p>",
"   <p>",
"    In our practice, we continue rhGH therapy if the growth velocity remains above 2",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    than the baseline pretreatment growth rate. Treatment is discontinued if one of the following circumstances occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27881/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Closed epiphyses",
"     </li>",
"     <li>",
"      Development of an active neoplastic disorder",
"     </li>",
"     <li>",
"      Hypersensitivity to rhGH or components of its formulation",
"     </li>",
"     <li>",
"      Increased intracranial pressure",
"     </li>",
"     <li>",
"      Noncompliance",
"     </li>",
"     <li>",
"      Severe hyperparathyroidism based on CKD stage: parathyroid hormone level &gt;400",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      for patients with CKD stage 2 through 4 and &gt;900",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      for patients with CKD stage 5.",
"     </li>",
"     <li>",
"      A dose reduction (eg, 50 percent of the recommended dose) may be considered when the height goal is achieved based on midparental height.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth impairment is a common problem in children with chronic kidney disease (CKD) and is associated with significant morbidity and mortality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the mechanisms underlying growth impairment are not completely understood, clinical and experimental evidence demonstrate that disturbances of growth hormone (GH) metabolism and its main mediator, insulin-like growth factor-I (IGF-I), are the primary pathogenetic mechanisms for poor growth in children with CKD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36713?source=see_link&amp;anchor=H113914234#H113914234\">",
"       \"Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease\", section on 'Pathogenesis: Disturbance of GH/IGF-I axis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both clinical trials and observational data from a large registry have shown that",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"       recombinant human growth hormone",
"      </a>",
"      (rhGH) therapy improves growth in children with CKD in all clinical settings: patients with CKD without renal replacement therapy, patients undergoing dialysis therapy, and patients with a functioning renal allograft. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of rhGH therapy is for children with CKD to attain normal final height. The minimal therapeutic aim should be a height greater than the third percentile of the general population. (See",
"      <a class=\"local\" href=\"#H170177130\">",
"       'Goal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend rhGH be initiated in children with CKD when the following criteria have been met (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All other amenable risk factors for growth impairment have been addressed. These include inadequate nutrition, metabolic acidosis, fluid and electrolyte abnormalities, anemia, and renal osteodystrophy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17240?source=see_link&amp;anchor=H359697775#H359697775\">",
"       \"Prevention and management of growth failure in children with chronic kidney disease\", section on 'Supportive measures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Estimated glomerular filtration rate is less than 75",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      .",
"     </li>",
"     <li>",
"      There is evidence of growth impairment; the mean Z-score for growth velocity &lt;-2",
"      <strong>",
"       or",
"      </strong>",
"      mean Z-score for height based on age and gender &lt;-1.88 (",
"      <a class=\"graphic graphic_figure graphicRef70382 \" href=\"UTD.htm?6/6/6253\">",
"       figure 3",
"      </a>",
"      ). The following calculators can be used to determine the Z-score for height for boys, girls, and infants (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?21/47/22262?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?22/7/22646?source=see_link\">",
"       calculator 2",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?33/34/34339?source=see_link\">",
"       calculator 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      There is no evidence of active malignancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, earlier intervention at a younger age (before six years of age) and early in the course of the renal failure leads to a more robust response to rhGH, which is more likely to result in achieving the goal of a normal final height. (See",
"      <a class=\"local\" href=\"#H170177383\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When rhGH therapy is given to children with CKD, we recommend an initial daily dose of 0.045 to 0.05",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      body weight (corresponds to a daily dose of 4 international units (IU) per m",
"      <sup>",
"       2",
"      </sup>",
"      body surface area therapy) given by subcutaneous injection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The dose of rhGH is greater than what is normally given to GH-deficient children, as children with CKD require pharmacologic rather than replacement dosing. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Dose of rhGH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An adequate growth response is defined as a growth velocity that is greater than 2",
"      <span class=\"nowrap\">",
"       cm/year",
"      </span>",
"      over the baseline rate prior to rhGH therapy. In patients who fail to have an adequate response, evaluation consists of assessments of patient compliance, correct dosing, and whether there are contributing factors for growth impairment. (See",
"      <a class=\"local\" href=\"#H1446970\">",
"       'Response to rhGH'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H170177779\">",
"       'Failure of response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although prolonged rhGH therapy does not appear to be associated with any major adverse effects, we suggest that patients treated long term with rhGH be monitored for glucose metabolic abnormalities (serum glucose), increased intracranial pressure (funduscopic examination), renal function (serum creatinine), and if symptomatic, hip radiographs to detect slipped capital femoral epiphysis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1446977\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/1\">",
"      Andr&eacute; JL, Bourquard R, Guillemin F, et al. Final height in children with chronic renal failure who have not received growth hormone. Pediatr Nephrol 2003; 18:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/2\">",
"      Mahan JD, Warady BA, Consensus Committee. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr Nephrol 2006; 21:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/3\">",
"      T&ouml;nshoff, B, Mehls, O. Growth retardation in children with chronic renal insufficiency: Current aspects of pathophysiology and treatment. J Nephrol 1995; 8:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/4\">",
"      Tom A, McCauley L, Bell L, et al. Growth during maintenance hemodialysis: impact of enhanced nutrition and clearance. J Pediatr 1999; 134:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/5\">",
"      Kari JA, Gonzalez C, Ledermann SE, et al. Outcome and growth of infants with severe chronic renal failure. Kidney Int 2000; 57:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/6\">",
"      Boirie Y, Broyer M, Gagnadoux MF, et al. Alterations of protein metabolism by metabolic acidosis in children with chronic renal failure. Kidney Int 2000; 58:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/7\">",
"      T&ouml;nshoff B, Kiepe D, Ciarmatori S. Growth hormone/insulin-like growth factor system in children with chronic renal failure. Pediatr Nephrol 2005; 20:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/8\">",
"      Mehls O, Ritz E, Hunziker EB, et al. Improvement of growth and food utilization by human recombinant growth hormone in uremia. Kidney Int 1988; 33:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/9\">",
"      Powell DR, Durham SK, Liu F, et al. The insulin-like growth factor axis and growth in children with chronic renal failure: a report of the Southwest Pediatric Nephrology Study Group. J Clin Endocrinol Metab 1998; 83:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/10\">",
"      Bereket A, Lang CH, Blethen SL, et al. Growth hormone treatment in growth retarded children with end stage renal failure: effect on free/dissociable IGF-I levels. J Pediatr Endocrinol Metab 1997; 10:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/11\">",
"      Santos F, Moreno ML, Neto A, et al. Improvement in growth after 1 year of growth hormone therapy in well-nourished infants with growth retardation secondary to chronic renal failure: results of a multicenter, controlled, randomized, open clinical trial. Clin J Am Soc Nephrol 2010; 5:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/12\">",
"      Van Dyck M, Gyssels A, Proesmans W, et al. Growth hormone treatment enhances bone mineralisation in children with chronic renal failure. Eur J Pediatr 2001; 160:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/13\">",
"      Guest G, B&eacute;rard E, Crosnier H, et al. Effects of growth hormone in short children after renal transplantation. French Society of Pediatric Nephrology. Pediatr Nephrol 1998; 12:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/14\">",
"      Fine RN, Stablein D, Cohen AH, et al. Recombinant human growth hormone post-renal transplantation in children: a randomized controlled study of the NAPRTCS. Kidney Int 2002; 62:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/15\">",
"      Powell DR, Liu F, Baker BK, et al. Modulation of growth factors by growth hormone in children with chronic renal failure. The Southwest Pediatric Nephrology Study Group. Kidney Int 1997; 51:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/16\">",
"      Fine RN, Kohaut EC, Brown D, Perlman AJ. Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group. J Pediatr 1994; 124:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/17\">",
"      Hodson EM, Willis NS, Craig JC. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev 2012; 2:CD003264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/18\">",
"      Seikaly MG, Salhab N, Warady BA, Stablein D. Use of rhGH in children with chronic kidney disease: lessons from NAPRTCS. Pediatr Nephrol 2007; 22:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/19\">",
"      Fine RN, Kohaut E, Brown D, et al. Long-term treatment of growth retarded children with chronic renal insufficiency, with recombinant human growth hormone. Kidney Int 1996; 49:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/20\">",
"      Seikaly MG, Waber P, Warady BA, Stablein D. The effect of rhGH on height velocity and BMI in children with CKD: a report of the NAPRTCS registry. Pediatr Nephrol 2009; 24:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/21\">",
"      T&ouml;nshoff B, Dietz M, Haffner D, et al. Effects of two years of growth hormone treatment in short children with renal disease. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Acta Paediatr Scand Suppl 1991; 379:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/22\">",
"      T&ouml;nshoff B, Mehis O, Heinrich U, et al. Growth-stimulating effects of recombinant human growth hormone in children with end-stage renal disease. J Pediatr 1990; 116:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/23\">",
"      Nissel R, Lindberg A, Mehls O, et al. Factors predicting the near-final height in growth hormone-treated children and adolescents with chronic kidney disease. J Clin Endocrinol Metab 2008; 93:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/24\">",
"      Schaefer F, W&uuml;hl E, Haffner D, Mehls O. Stimulation of growth by recombinant human growth hormone in children undergoing peritoneal or hemodialysis treatment. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Adv Perit Dial 1994; 10:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/25\">",
"      B&eacute;rard E, Crosnier H, Six-Beneton A, et al. Recombinant human growth hormone treatment of children on hemodialysis. French Society of Pediatric Nephrology. Pediatr Nephrol 1998; 12:304.",
"     </a>",
"    </li>",
"    <li>",
"     North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual dialysis report. https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/27\">",
"      Nissel R, Br&aacute;zda I, Feneberg R, et al. Effect of renal transplantation in childhood on longitudinal growth and adult height. Kidney Int 2004; 66:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/28\">",
"      T&ouml;nshoff B, Haffner D, Mehls O, et al. Efficacy and safety of growth hormone treatment in short children with renal allografts: three year experience. Members of the German Study Group for Growth Hormone Treatment in Children with Renal Allografts. Kidney Int 1993; 44:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/29\">",
"      Acott PD, Pernica JM. Growth hormone therapy before and after pediatric renal transplant. Pediatr Transplant 2003; 7:426.",
"     </a>",
"    </li>",
"    <li>",
"     T&ouml;nshoff B, Mehls O. Use of rhGH post transplant in children. In: Pediatric Renal Transplantation, Wiley &amp; Sons, New York 1994. p.441.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/31\">",
"      Hokken-Koelega AC, Stijnen T, de Jong RC, et al. A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplant. Kidney Int Suppl 1996; 53:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/32\">",
"      Fine RN, Stablein D. Long-term use of recombinant human growth hormone in pediatric allograft recipients: a report of the NAPRTCS Transplant Registry. Pediatr Nephrol 2005; 20:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/33\">",
"      Fine RN, Attie KM, Kuntze J, et al. Recombinant human growth hormone in infants and young children with chronic renal insufficiency. Genentech Collaborative Study Group. Pediatr Nephrol 1995; 9:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/34\">",
"      Mencarelli F, Kiepe D, Leozappa G, et al. Growth hormone treatment started in the first year of life in infants with chronic renal failure. Pediatr Nephrol 2009; 24:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/35\">",
"      Haffner D, Schaefer F, Nissel R, et al. Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. N Engl J Med 2000; 343:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/36\">",
"      Hokken-Koelega AC, Stijnen T, de Ridder MA, et al. Growth hormone treatment in growth-retarded adolescents after renal transplant. Lancet 1994; 343:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/37\">",
"      B&eacute;rard E, Andr&eacute; JL, Guest G, et al. Long-term results of rhGH treatment in children with renal failure: experience of the French Society of Pediatric Nephrology. Pediatr Nephrol 2008; 23:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/38\">",
"      Haffner D, W&uuml;hl E, Schaefer F, et al. Factors predictive of the short- and long-term efficacy of growth hormone treatment in prepubertal children with chronic renal failure. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. J Am Soc Nephrol 1998; 9:1899.",
"     </a>",
"    </li>",
"    <li>",
"     National Kidney Foundation Kidney Disease Outcomes Quality Initiative (2000) Clinical practice guidelines for nutrition in chronic renal failure. National Kidney Foundation. Accessed 15 Jan 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/40\">",
"      Fine RN, Fine SE, Sherman BM. Absorption of recombinant human growth hormone (rhGH) following intraperitoneal instillation. Perit Dial Int 1989; 9:91.",
"     </a>",
"    </li>",
"    <li>",
"     T&ouml;nshoff B, Fine R. Growth and growth hormone treatment in children with chronic renal insufficiency. In: Clinical Dialysis, Medical Publishing Division /The McGraw-Hill Companies Inc, 2005. p.611.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/42\">",
"      Fine RN, Ho M, Tejani A, Blethen S. Adverse events with rhGH treatment of patients with chronic renal insufficiency and end-stage renal disease. J Pediatr 2003; 142:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/43\">",
"      Dharnidharka VR, Talley LI, Martz KL, et al. Recombinant growth hormone use pretransplant and risk for post-transplant lymphoproliferative disease--a report of the NAPRTCS. Pediatr Transplant 2008; 12:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/44\">",
"      Filler G, Franke D, Amendt P, Ehrich JH. Reversible diabetes mellitus during growth hormone therapy in chronic renal failure. Pediatr Nephrol 1998; 12:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/45\">",
"      Stefanidis CJ, Papathanassiou A, Michelis K, et al. Diabetes mellitus after therapy with recombinant human growth hormone (rhGH). Br J Clin Pract Suppl 1996; 85:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/46\">",
"      Yadin O, Fine RN. Long-term use of recombinant human growth hormone in children with chronic renal insufficiency. Kidney Int Suppl 1997; 58:S114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27881/abstract/47\">",
"      Koller EA, Stadel BV, Malozowski SN. Papilledema in 15 renally compromised patients treated with growth hormone. Pediatr Nephrol 1997; 11:451.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6140 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27881=[""].join("\n");
var outline_f27_14_27881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70626147\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70626168\">",
"      Z-height score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64686581\">",
"      Growth or height velocity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H164342890\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H660580\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H660587\">",
"      NAPTRCS observational data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70624823\">",
"      Specific populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H70624946\">",
"      - Prepubertal patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H70624954\">",
"      CKD without RRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H70625437\">",
"      Dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H70625593\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H660666\">",
"      - Infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pubertal children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70626075\">",
"      Final adult height",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INITIATION OF rhGH THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170177130\">",
"      Goal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170176797\">",
"      Timing and indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H162284220\">",
"      - Predictors for growth response to rhGH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H170177383\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dose of rhGH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Frequency and mode of administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H170177771\">",
"      MONITORING RESPONSE AND FOR ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1446970\">",
"      Response to rhGH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1446977\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170177779\">",
"      Failure of response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6140\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6140|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/37/4692\" title=\"figure 1\">",
"      Height velocity in boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/0/16387\" title=\"figure 2\">",
"      Height velocity in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/6/6253\" title=\"figure 3\">",
"      Normal growth rate in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/47/22262?source=related_link\" title=\"calculator 1\">",
"      Calculator: CDC height for age percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?22/7/22646?source=related_link\" title=\"calculator 2\">",
"      Calculator: CDC height for age percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?33/34/34339?source=related_link\" title=\"calculator 3\">",
"      Calculator: CDC/NCHS infant length for age percentiles (&lt;36 months)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36713?source=related_link\">",
"      Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17240?source=related_link\">",
"      Prevention and management of growth failure in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=related_link\">",
"      Slipped capital femoral epiphysis (SCFE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=related_link\">",
"      Treatment of growth hormone deficiency in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_14_27882="Management and prognosis of parapneumonic effusion and empyema in children";
var content_f27_14_27882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management and prognosis of parapneumonic effusion and empyema in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/14/27882/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27882/contributors\">",
"     Ibrahim A Janahi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27882/contributors\">",
"     Khoulood Fakhoury, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/14/27882/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27882/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27882/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/14/27882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/14/27882/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/14/27882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parapneumonic effusion is defined as pleural effusion associated with lung infection (ie, pneumonia). These effusions result from the spread of inflammation and infection to the pleura. Much less commonly, infections in other adjacent areas, such as the retropharyngeal, vertebral, abdominal, and retroperitoneal spaces may spread to the pleura resulting in the development of effusion.",
"   </p>",
"   <p>",
"    Early in the course of parapneumonic effusion, the pleura becomes inflamed; subsequent leakage of proteins, fluid, and leukocytes into the pleural space forms the effusion. At the time of formation, the pleural effusion is usually sterile with a low leukocyte count. With time, bacteria invade the fluid, resulting in empyema, which is defined as the presence of grossly purulent fluid in the pleural cavity. The development of pleural empyema is determined by a balance between host resistance, bacterial virulence, and timing of presentation for medical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of parapneumonic effusion and empyema in children will be reviewed here. The epidemiology, etiology, pathophysiology, clinical presentation, and evaluation of parapneumonic effusion and empyema in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=see_link\">",
"     \"Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation and management of parapneumonic effusion in adults also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link\">",
"     \"Imaging of pleural effusions in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the improvement in the technology available for diagnosing and treating empyema, the management of empyema in children remains controversial. With limited evidence from controlled studies with random allocation, there is no consensus on the role of medical versus surgical management [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Data cannot be extrapolated from studies in adults, in whom the morbidity and mortality are increased, often related to underlying lung disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of therapy include sterilization of the pleural cavity, resolution of pleural fluid, and reexpansion of the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/3\">",
"     3",
"    </a>",
"    ]. The initial management depends upon the stage of the disease at the time of presentation and the clinical status of the child. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to hospitalize a given patient with pneumonia depends upon the patient's clinical status, age, and associated conditions. As a general rule, patients with lobar pneumonia who are under six months of age, those with evidence of bacteremia or respiratory compromise, and those who have failed outpatient management, should be admitted to a hospital for intravenous antibiotic therapy and close observation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients with complicated pneumonia with parapneumonic effusions will require hospitalization for further management. Occasionally patients with small parapneumonic effusions who are clinically well and are responding to outpatient therapy can be managed without hospitalization, providing that they are followed closely to monitor progress. Transfer to a facility with specialists in pediatric pulmonology, pediatric surgery, and pediatric anesthesia should be considered early in the care of children who may require video-assisted thoracoscopy (VATS) or fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parapneumonic effusion and empyema is a disease process that evolves over time and different management strategies are appropriate at different stages [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/3\">",
"     3",
"    </a>",
"    ]. In cases with mild symptoms of short duration, initial therapy may include broad-spectrum oral antibiotics and close observation with chest radiographs on an outpatient basis. In cases with increased severity, hospitalization and intravenous antibiotics are usually indicated.",
"   </p>",
"   <p>",
"    Children who have effusions that are enlarging",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    compromising respiratory function require drainage of pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. This can be achieved through thoracentesis or chest drain placement.",
"   </p>",
"   <p>",
"    Drainage of loculated or organized pleural effusion usually requires more aggressive therapy. This may include fibrinolytic therapy, or debridement of the pleural space via VATS, or thoracotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Management options may be limited by the availability of appropriately trained pediatric thoracic surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. Early involvement of a surgeon in the decision-making process helps to ensure that timely surgical intervention can occur if it is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing for surgical intervention is controversial. Some studies indicate that surgical intervention is seldom needed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/8-11\">",
"     8-11",
"    </a>",
"    ], whereas others suggest clear benefits from early pleural debridement or decortication in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Information from these retrospective case series, usually from single institutions, is biased by local practice, and if encompassing long periods of time, influenced by changes in prevalent organisms and evolution of imaging and surgical techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,3,15,16\">",
"     2,3,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Surgical versus medical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether surgery should be the initial treatment of choice or reserved for failed medical management is not definitively known [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of 67 studies published between 1981 and 2004 regarding the treatment of empyema in children aggregated the data according to the mode of therapy (nonoperative versus primary operative) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/17\">",
"     17",
"    </a>",
"    ]. The results are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef73858 \" href=\"UTD.htm?20/50/21292\">",
"     table 1",
"    </a>",
"    ). Treatment with antibiotics and tube thoracostomy was successful in 76 percent of patients. However, avoidance of surgery appears to occur at the expense of increased duration of chest tube (10.6 versus 4.4 days), hospital stay (20 versus 10.8 days), and antibiotic therapy (21.3 versus 12.8 days) and mortality (3.3 versus 0 percent).",
"   </p>",
"   <p>",
"    The systematic review is subject to the same limitations as the included studies (eg, local bias, evolution of imaging and surgical techniques over time) as well as the lack of information regarding the method of diagnosis and stage of parapneumonic effusion at the time of treatment. Nonetheless, the conclusions are consistent with clinical experience.",
"   </p>",
"   <p>",
"    Two randomized controlled trials addressing treatment of parapneumonic effusion in children were published after the systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first, surgical therapy (VATS) was compared to conventional medical therapy with antibiotics and chest tube drainage (with or without fibrinolysis in 18 children with large parapneumonic effusion) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/18\">",
"       18",
"      </a>",
"      ]. As in the systematic review, increased hospital stay and duration of chest tube drainage were noted in the group treated with conventional therapy.",
"     </li>",
"     <li>",
"      The second compared VATS to medical therapy with fibrinolysis and found no difference in clinical outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/19\">",
"       19",
"      </a>",
"      ]. In this trial, 60 children (&lt;16 years) with radiographic evidence of empyema and indications for drainage were randomly assigned to treatment with primary VATS or percutaneous chest tube drainage with intrapleural urokinase. The primary outcome measure was length of hospital stay after intervention and there was no difference between groups (95% CI -2 to 1 day). The median hospital stay after intervention was 6 days for both groups, with a range of 3 to 16 days for those treated with VATS and 4 to 25 days for those with fibrinolysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the aggregate, these studies indicate that the outcome in children who do not have an underlying lung disorder is almost always excellent. However, they also suggest that early surgical intervention with VATS decreases the duration of hospital stay and chest tube drainage. The finding that clinical outcomes are comparable with VATS and fibrinolytic therapy suggests that fibrinolytic therapy is an acceptable alternative to VATS, particularly in institutions where a pediatric surgeon is not readily available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Algorithmic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Algorithmic approaches to management of parapneumonic effusion and empyema have been developed by the British Thoracic Society (BTS), the American Pediatric Surgical Association (APSA), and the Pediatric Infectious Diseases Society (PIDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,5,20\">",
"     2,5,20",
"    </a>",
"    ]. These approaches are similar, treating symptomatic moderate to large simple effusions with drainage and antibiotics, and complicated effusions with either early surgical drainage (VATS or mini-thoracotomy) or fibrinolysis and chest tube drainage. Additional recommendations from the BTS guidelines are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef78355 \" href=\"UTD.htm?41/34/42540\">",
"     table 2",
"    </a>",
"    ). These approaches are described in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef76277 \" href=\"UTD.htm?18/40/19073\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    At Texas Children's Hospital, the following variation on the algorithm is used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who present with large effusions requiring drainage, ultrasonography is performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the fluid is free flowing, the patient undergoes thoracentesis with drainage of as much fluid as possible (but no more than 10 to 20",
"      <span class=\"nowrap\">",
"       mL/kg).",
"      </span>",
"      The patient is treated with empiric antibiotics and observed, without drainage, for 48 hours. If fever and fluid collection persist, with evidence of loculation on ultrasonography, then VATS is performed with concurrent insertion of a chest tube (typically a large bore tube to avoid possible blockage by the thick, purulent fluid).",
"     </li>",
"     <li>",
"      Patients who present with a loculated effusion, documented by ultrasonography, undergo VATS for diagnosis and treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with a small effusion (eg, &lt;10 mm on lateral decubitus radiograph or opacifying less than one-fourth of the hemithorax [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/5\">",
"       5",
"      </a>",
"      ]) are treated with broad-spectrum oral antibiotics and close observation with chest radiographs on an outpatient basis (",
"      <a class=\"graphic graphic_algorithm graphicRef78748 \" href=\"UTD.htm?29/48/30478\">",
"       algorithm 2",
"      </a>",
"      ). &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach has resulted in no major complications, more rapid clinical improvement, and earlier discharge from the hospital than previous management strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative approach has been described in which children admitted with a moderate pleural effusion were treated with a trial of empirically selected antibiotics for 24 to 72 hour period before thoracentesis or other drainage procedure; patients who did not respond clinically underwent drainage procedure (chest tube, VATS or thoracotomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/22\">",
"     22",
"    </a>",
"    ]. Antibiotics alone were successful in about half of these children.",
"   </p>",
"   <p>",
"    There are few prospective, randomized trials comparing the various treatment options. Additional trials will be necessary before standards based on high-quality evidence for the treatment of empyema in children can be developed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care for children with parapneumonic effusion may include antipyretics, analgesia, and early mobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. Children with empyema are invariably febrile; antipyretics should be used for comfort, with the caveat that resolution of fever is one of the indicators of clinical progress [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. Analgesia should be administered for pleuritic pain, which may interfere with breathing and affect the child's willingness to cough. Adequate analgesia may prevent secondary scoliosis and will help with early mobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. Sedatives and agents that may cause central respiratory depression should be used only if needed, and when needed should be used cautiously with close monitoring of respiratory status.",
"   </p>",
"   <p>",
"    Children with parapneumonic effusions may become dehydrated as a result of poor intake and increased losses from fever and tachypnea. Intravenous fluids should be administered if the child refuses oral intake or is unable to drink. However, close attention must be paid to fluid balance since these children also are at risk to develop the SIADH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bronchodilator therapy has no role in treatment of children with parapneumonic effusions and may potentially worsen their",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    mismatch, exacerbating hypoxemia. Chest physiotherapy is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;All children with parapneumonic effusion should be treated with antibiotic therapy. In children with a small effusion (eg, &lt;10 mm on lateral decubitus radiograph or opacifying less than one-fourth of the hemithorax [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/5\">",
"     5",
"    </a>",
"    ]), this may include broad-spectrum oral antibiotics and close observation with chest radiographs on an outpatient basis (",
"    <a class=\"graphic graphic_algorithm graphicRef78748 \" href=\"UTD.htm?29/48/30478\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/5\">",
"     5",
"    </a>",
"    ]. Children with moderate to large effusions or empyema should be hospitalized and treated with intravenous antibiotics in doses adequate to ensure pleural penetration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. If thoracocentesis or drainage of pleural fluid is indicated, pleural fluid should be sent for culture and analysis prior to beginning antibiotics. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Thoracentesis'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    The choice of antibiotic(s) should be based upon the suspected causative organism. Empiric coverage should be geared toward the most common organisms causing community acquired or nosocomial pneumonia in the patient's age group in",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    community or hospital, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link&amp;anchor=H12#H12\">",
"     \"Inpatient treatment of pneumonia in children\", section on 'Empiric therapy'",
"    </a>",
"    .) Antibiotic therapy should ultimately be modified based upon the sensitivity results if and when they are available.",
"   </p>",
"   <p>",
"    For non&ndash;life-threatening infection, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    with addition of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    (for suspected community-acquired methicillin-resistant S. aureus [CA-MRSA]) is suggested for empiric therapy, pending the results of cultures.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     Ampicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/46/14054?source=see_link\">",
"     penicillin G",
"    </a>",
"    might also be considered as first-line drugs in fully immunized children in areas where local penicillin resistance in invasive strains of pneumococcus is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/5\">",
"     5",
"    </a>",
"    ]. The choice of first line antibiotics is mainly determined by the most common bacteriological etiology causing community acquired pneumonia in a given area. For life-threatening infection, vancomycin plus cefotaxime is selected because of the rising prevalence of drug resistant organisms.",
"   </p>",
"   <p>",
"    Antibiotic coverage for children with nosocomial parapneumonic effusion should include coverage of gram-negative organisms. Antibiotic coverage for children in whom aspiration is suspected (ie, those with neuromuscular disease or neurologic impairment) should include coverage of anaerobes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Community-acquired Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methicillin sensitive S. aureus should be treated with beta-lactam antibiotics. However, the number of reported cases of parapneumonic effusions caused by CA-MRSA is increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/24-28\">",
"     24-28",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    remains the drug of choice to treat MRSA. However, other antibacterial agents, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    , can be used if the organism is sensitive to them. If the child appears ill and S. aureus is suspected, it is reasonable to initiate therapy with vancomycin pending culture and sensitivity results. The use of newer anti-MRSA antibiotics should be reserved for the most resistant cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=see_link\">",
"     \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is the common practice in our institutions, as well as in many centers in the United Kingdom, to continue intravenous antibiotic therapy as long as the child is febrile [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. The duration of intravenous antibiotic therapy after resolution of fever and toxicity is controversial. There are no data from randomized controlled trials on appropriate length of therapy or whether the duration of therapy should vary depending upon the causative organism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. Some clinicians continue intravenous antibiotics for 48 hours after the patient becomes afebrile or after the chest drain is removed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. Others continue intravenous therapy for up to two weeks. In our experience, continuation of intravenous antibiotics for five days after resolution of fever is probably adequate. All patients should continue on oral therapy for two to three weeks thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     THORACENTESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If feasible, patients presenting with a moderate or large parapneumonic effusion should undergo a trial of fluid aspiration before starting antibiotic therapy. Cultures and gram stain performed on the aspirated pleural fluid help to direct antibiotic therapy. Additional techniques may be used to increase the yield of microbiologic diagnosis in children who have received antibiotics. These include: direct and enrichment culture for aerobic and anaerobic organisms, pneumococcal antigen detection (latex agglutination) and specific or broad range polymerase chain reaction (PCR). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=see_link&amp;anchor=H17#H17\">",
"     \"Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children\", section on 'Microbial analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other characteristics of the pleural fluid, such as pH, glucose, and LDH have been used to predict a need for drainage procedures. The Pediatric Infectious Disease Society (PIDS) does not recommend assessing these characteristics because the results rarely change management of a patient with community-acquired pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/5\">",
"     5",
"    </a>",
"    ]. However, these biochemical studies may be useful if the diagnosis of empyema is in doubt or in the setting of an underlying condition that might be responsible for the effusion, such as collagen-vascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=see_link&amp;anchor=H18#H18\">",
"     \"Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children\", section on 'Other studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During thoracentesis, as much fluid as possible should be slowly removed. The aspiration should be limited to 10 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    because rapid removal of large amounts of pleural fluid has been reported to cause pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] and worsening of respiratory status. If reaccumulation of fluid occurs after the initial thoracentesis, chest tube insertion is warranted. Repeated thoracentesis is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CHEST TUBES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large amounts of pleural fluid can be slowly drained using chest tubes with underwater seal systems. Chest tube placement should be considered for patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large amounts of free flowing pleural fluid",
"     </li>",
"     <li>",
"      Compromised pulmonary function (eg, severe hypoxemia, hypercapnia)",
"     </li>",
"     <li>",
"      Evidence of fibrinopurulent effusions (eg, pH &lt;7.0, glucose &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.22",
"      <span class=\"nowrap\">",
"       mmol/L],",
"      </span>",
"      LDH &gt;1000 IU [16.67",
"      <span class=\"nowrap\">",
"       kat/L],",
"      </span>",
"      positive gram stain, frank pus)",
"     </li>",
"     <li>",
"      Failure to respond to 48 to 72 hours of antibiotic therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The chest tube should be left in place until fluid drainage becomes minimal (less than 10 to 15 mL per 24 hours).",
"   </p>",
"   <p>",
"    In a systematic review of 67 studies regarding treatment of empyema in children published between 1981 and 2004, data were aggregated according to mode of therapy (nonoperative versus primary operative) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/17\">",
"     17",
"    </a>",
"    ]. Among children treated with antibiotics and chest tube drainage, 23.6 percent eventually required operative intervention. The aggregate mortality rate was 3.3 percent. The average duration of chest tube, antibiotic therapy, and hospital stay was 10.6 days, 21.3 days, and 20 days, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Size of tube",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is controversy regarding the optimum size of chest tube. Good data to recommend one size of chest tube over another are lacking. The British Thoracic Society (BTS) guidelines suggest that in the absence of evidence that large bore tubes confer any advantage over smaller tubes, smaller tubes (including pigtail catheters) should be used whenever possible to minimize patient discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Practices vary among institutions. The size and type of chest tubes generally depend upon the type of fluid in the pleural cavity. Free flowing fluid can be adequately drained by flexible small-bore drains (ie, pigtails), whereas thick pus may require large bore drains with holes of increased diameter. Even large bore drains are usually inadequate once loculations develop because the holes become obstructed by the fibrinous material. In such cases, more aggressive therapy is required (eg, VATS or fibrinolytic therapy, which is discussed below). Many pediatric surgeons prefer to use large tubes after the VATS procedure to provide adequate drainage and less chance of tube blockage during the recovery period.",
"   </p>",
"   <p>",
"    When combined with fibrinolytic therapy, the use of small chest tubes may provide some advantages over large tubes. In post-hoc analysis of one of the studies evaluating fibrinolytic therapy in children, the use of a smaller drain was associated with a shorter hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, one retrospective case series noted that the use of pigtail catheters and fibrinolytic therapy for loculated effusion was superior to surgical stiff drains and comparable to thoracotomy in terms of duration of fever, parental report of clinical improvement, and length of hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography can be used to guide chest tube placement. The procedure can be performed with ultrasonography or the skin can be marked to indicate the optimum site for drain insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. If the skin is marked, chest tube insertion must be performed with the child in the same position as he or she was when the skin was marked [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. Care must be taken to ensure that the child will be able to lie down without discomfort once the drain is in place. Adequate analgesia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sedation with appropriate monitoring should be employed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest radiographs should be obtained after insertion to ensure that there is no pneumothorax and to verify position [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. However, an effectively functioning tube should not be repositioned solely on the basis of a radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;All chest tubes should be connected to a unidirectional drainage system, which must be kept below the level of the patient's chest at all times [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. The underwater seal system is frequently used. This system is comprised of a tube placed under water at a depth of approximately 1 to 2 cm, and a side vent, which either permits escape of air or is connected to a suction pump [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. The system should be assessed daily for the amount of drainage, the presence of bubbling, and the presence of swing in the fluid with respiration (which confirms tube patency and appropriate position in the pleural cavity).",
"   </p>",
"   <p>",
"    Reexpansion pulmonary edema has been reported after drainage of large effusions in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/29\">",
"     29",
"    </a>",
"    ] and in children with malignant lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/30\">",
"     30",
"    </a>",
"    ], but is otherwise rare in children. Nonetheless, to prevent this complication, the drain should be clamped for one hour after drainage of the initial 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of pleural fluid. In large children and adolescents, although there is no high-quality evidence on which to base this recommendation, it is suggested that no more than 1500 mL of fluid be drained at one time, or that drainage should be slowed to 500",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,38\">",
"     2,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clamped drains must be immediately unclamped if there are any signs of clinical deterioration (eg, breathlessness, chest pain). This is because tension pneumothorax may develop in patients with air leak (which may be subclinical) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Air in the pleural space is indicated by air bubbles in the water. Continuous bubbling suggests a continued visceral pleural air leak or, in patients on suction, that the drain is partly out of the thorax and one of the tube's drainage holes is open to the atmosphere [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. Because of the risk of developing a tension pneumothorax, a bubbling chest drain should never be clamped [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,38\">",
"     2,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Troubleshooting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cessation of fluid drainage may indicate kinking or blockage of the tube by thick exudative fluid, pus, or debris [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. Small soft drains are prone to kinking at the exit site, particularly in young mobile children. Obstruction of the tube by pus may be relieved by carefully flushing with normal saline (10 mL should be adequate in a small bore drain) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. A drain that cannot be unblocked should be removed and replaced if significant pleural fluid remains [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, drainage may cease if the fluid becomes loculated or the suction holes of the tube are outside the pleural space [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest tube should be removed once there is clinical resolution and minimal chest tube drainage (less than 10 to 15 mL per 24 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]. It is not necessary to wait for complete resolution of drainage since the tube itself may act as a stimulus for pleural exudative reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/8,39\">",
"     8,39",
"    </a>",
"    ] and increases the risk of secondary infection. There is no need to clamp the chest tube before its removal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors to consider in clinical resolution are discussed below. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Monitoring response to therapy'",
"    </a>",
"    below.) They include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The child's temperature and well-being",
"     </li>",
"     <li>",
"      Chest radiographic and ultrasonographic appearance",
"     </li>",
"     <li>",
"      Fall in white blood cell count and acute phase reactants",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During chest tube removal, analgesia should be used, and sedation may be necessary in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. Local anesthetic cream applied to the adjacent skin three hours before chest tube removal may be as effective as intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    for pain control [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/40\">",
"     40",
"    </a>",
"    ]. The chest tube should be removed with a brisk firm movement while the child performs the Valsalva maneuver or during expiration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. A chest radiograph should be taken shortly after chest tube removal to check for pneumothorax.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of chest tubes include bleeding, failure to drain adequately, wound infection at the exit site, development of bronchopleural fistula, persistent atelectasis, and laceration of the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/36,41\">",
"     36,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     FIBRINOLYTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of fibrinolytic drugs to lyse the fibrinous strands in loculated parapneumonic effusions has been described in adults and children. These drugs include urokinase, streptokinase, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=see_link\">",
"     alteplase",
"    </a>",
"    (tissue plasminogen activator, tPA).",
"   </p>",
"   <p>",
"    The British Thoracic Society (BTS) guidelines and a position paper by the American Pediatric Surgical Association suggest fibrinolytic therapy as a component of the medical option for patients in whom the pleural fluid is thick or loculated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. We agree that fibrinolytic therapy is a reasonable alternative to VATS, and suggest it as an alternative for children with loculated parapneumonic effusion who are hospitalized at institutions lacking a pediatric surgeon who is trained in VATS. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Algorithmic approaches'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of fibrinolytic therapy in complicated parapneumonic effusion and empyema has been studied in adults. A meta-analysis of five trials comparing intrapleural fibrinolytic therapy versus placebo revealed a reduction in death and need for surgery among patients who received fibrinolytic therapy that was not statistically significant (pooled risk ratio 0.55, 95% CI 0.28-1.07) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link&amp;anchor=H15#H15\">",
"     \"Parapneumonic effusion and empyema in adults\", section on 'Empyema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of fibrinolytic therapy in the management of parapneumonic effusion in children also has been described, primarily in case series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/43-54\">",
"     43-54",
"    </a>",
"    ]. These reports suggest that children treated with fibrinolytic therapy have increased pleural drainage and often have successful outcomes without surgery.",
"   </p>",
"   <p>",
"    Controlled trials of fibrinolytic therapy versus saline in children have had inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/31,55\">",
"     31,55",
"    </a>",
"    ], which may be related to differences in disease stage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/52\">",
"     52",
"    </a>",
"    ] or in the fibrinolytic agent, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 60 children with parapneumonic effusion were randomly assigned to receive either intrapleural urokinase or saline, but otherwise managed at the discretion of the managing pediatrician [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/31\">",
"       31",
"      </a>",
"      ]. Children in the urokinase group had a shorter hospital stay (7.4 versus 9.5 days after entry into the study) with no major adverse effects. However, by chance, children in the placebo group had longer duration of illness before entry into the study and marginally lower oxygen saturation.",
"     </li>",
"     <li>",
"      In the second trial, 40 children with advanced stage empyema were randomly assigned to receive intrapleural streptokinase or normal saline in addition to intercostal drainage [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/55\">",
"       55",
"      </a>",
"      ]. There was no difference in clinical or ultrasonographic outcome between the groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another randomized study, comparing fibrinolytic therapy with urokinase to VATS, found no difference in length of hospital stay after intervention between groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/56\">",
"     56",
"    </a>",
"    ]. This study is discussed in greater detail above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Surgical versus medical treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from controlled studies that any one of the fibrinolytic agents is more effective than the others is lacking. Only urokinase has been studied in a controlled fashion in children, and thus is recommended by the BTS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. However, urokinase is no longer available in North America. The one study comparing urokinase and streptokinase in adults found them to be equally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/57\">",
"     57",
"    </a>",
"    ]. However, in the",
"    <span class=\"nowrap\">",
"     BTS/MRC",
"    </span>",
"    multicenter intrapleural streptokinase trial, streptokinase had no beneficial effect in adult empyema [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition, the risk-to-benefit ratio for streptokinase is higher than for the other fibrinolytics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. In one retrospective case series, thoracostomy tube drainage was increased with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=see_link\">",
"     alteplase",
"    </a>",
"    compared to urokinase [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/48\">",
"     48",
"    </a>",
"    ]. The choice of agent depends upon availability, with urokinase being preferred if it is available, followed by alteplase (recombinant tissue plasminogen activator) and streptokinase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link&amp;anchor=H15#H15\">",
"     \"Parapneumonic effusion and empyema in adults\", section on 'Empyema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Technique and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of fibrinolytic therapy, which is performed by instilling the drug through the chest tube, or irrigation at the time of thoracoscopy, may cause discomfort. Adequate sedation and or analgesia should be provided.",
"   </p>",
"   <p>",
"    A number of different doses of these agents have been used in various studies. The following technique and dose for urokinase is recommended in the BTS guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ] and is also included in the PIDS guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urokinase 40,000 units in 40 mL 0.9 percent saline for children one year and older, and 10,000 units in 10 mL 0.9 percent saline for children younger than 1 year. This dose should be administered twice daily (with a four-hour dwell time) for three days; additional doses can be administered if the response is incomplete after six doses. Intrapleural",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/17/43285?source=see_link\">",
"       bupivacaine",
"      </a>",
"      (0.5 to 1.0",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of a 0.25 percent solution) can be administered with urokinase if the child finds it uncomfortable [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two approaches for treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=see_link\">",
"     alteplase",
"    </a>",
"    were described in the PIDS guidelines, based on clinical studies in which these regimens were safe and effective in children older than three months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/5\">",
"     5",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=see_link\">",
"       Alteplase",
"      </a>",
"      4 mg in 40 mL 0.9 percent saline, intrapleural. The first dose is given at time of chest tube placement with 1 hour dwell time, repeat every 24 hours for 3 days (total of 3 doses) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=see_link\">",
"       Alteplase",
"      </a>",
"      0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum: 3 mg) in 10-30 mL 0.9 percent saline, intrapleural. The first dose is given after pigtail catheter (or chest tube) placement, with a 45 minute to 1 hour dwell time, and repeated every 8 hours for 3 days (total of 9 doses) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinolytic therapy should not be performed in patients who have bronchopleural fistula or chest tubes that are bubbling, suggestive of an air leak, since clamping of the chest tube in such a patient could result in tension pneumothorax. In addition, chest tubes that are clamped must be immediately unclamped if the child has any signs of clinical deterioration (eg, breathlessness, chest pain).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of fibrinolytic therapy include fever, discomfort, bleeding, and anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/31,48,61\">",
"     31,48,61",
"    </a>",
"    ]. In the pediatric trials using urokinase",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=see_link\">",
"     alteplase",
"    </a>",
"    described above, minor side effects included discomfort during intrapleural injection and transient blood staining of the drainage fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/31,48\">",
"     31,48",
"    </a>",
"    ]. Rare immediate hypersensitivity reactions to urokinase have been reported in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/62\">",
"     62",
"    </a>",
"    ]. Intrapleural administration of streptokinase generates a systemic antibody response similar to that when the drug is administered intravenously [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/63\">",
"     63",
"    </a>",
"    ]; fever has been reported and other immunologic responses are possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SURGICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical therapy is usually required in late presenting cases (ie, those with symptoms for more than one week), particularly those with multiple loculations, and in those with concomitant medical conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. However, accurate prediction of the need for surgical intervention is not possible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. Early involvement of a surgeon in the decision-making process helps to ensure that timely surgical intervention can occur if it is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether surgery should be the initial treatment of choice or reserved for failed medical management is not definitively known [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Surgical versus medical treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Situations in which surgical intervention is usually necessary include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of clinical and radiologic response to initial medical management (eg, antibiotics, chest tube drainage, fibrinolytic therapy)",
"     </li>",
"     <li>",
"      Persistent sepsis in association with persistent pleural collection, despite chest tube drainage and antibiotics",
"     </li>",
"     <li>",
"      Complex empyema with significant lung pathology (eg, delayed presentation with a significant peel and trapped lung)",
"     </li>",
"     <li>",
"      Bronchopleural fistula with pyopneumothorax",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three surgical procedures have been described in the management of children with parapneumonic effusion: video-assisted thoracoscopy (VATS), minithoracotomy, and decortication [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. A chest drain is left in place after each of these procedures for continued drainage of fluid or pus. Provided that there is an appropriately trained pediatric surgeon, VATS is the preferred procedure because it is less invasive than open thoracotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Video-assisted thoracoscopy (VATS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video-assisted thoracoscopy (VATS) can be used to remove the thick fibrinous septations that prevent adequate drainage of pleural fluid via thoracentesis or chest tube. VATS permits debridement of fibrinous pyogenic material, breakdown of loculations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/14,66,67\">",
"     14,66,67",
"    </a>",
"    ], and drainage of pus from the pleural cavity under direct vision [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,68-70\">",
"     2,68-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized controlled trials to show that VATS is more effective",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    safer than the existing operative techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. However, there appears to be an international trend toward early surgical intervention with video-assisted thoracoscopy (VATS), with some centers advocating VATS as first-line therapy for empyema [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At Texas Children's Hospital, VATS is used as the ultimate therapy in approximately 70 percent of children with complicated parapneumonic effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/71\">",
"     71",
"    </a>",
"    ]. A review of the 10-year experience (1993-2002) with VATS at that institution suggested that early (&lt;48 hours after admission) compared with late VATS (&gt;48 hours after admission) significantly decreased the length of hospitalization (11.5 versus 15.2 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/21\">",
"     21",
"    </a>",
"    ]. A similar finding was reported in a systematic review of English- and Spanish-language articles on the treatment of empyema in children published between 1987 and 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it requires general anesthesia, VATS is otherwise safe and much less invasive than open thoracotomy with decortication, which is discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/14,56,66,72\">",
"     14,56,66,72",
"    </a>",
"    ]. VATS leaves two to three small scars [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,73\">",
"     2,73",
"    </a>",
"    ]. The use of VATS depends to a large extent upon the availability of the equipment and appropriately trained pediatric thoracic surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. However, it is commonly performed in children in many centers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/14,66,74-76\">",
"     14,66,74-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proponents of early VATS suggest if general anesthesia is necessary for simple drain insertion, the procedure may as well be combined with VATS if an appropriately trained surgeon is available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/68\">",
"     68",
"    </a>",
"    ]. Early VATS is reported to enhance the chance of full expansion of the collapsed lung [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. The failure rate increases in late presenting cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/69,72\">",
"     69,72",
"    </a>",
"    ], and in patients who undergo VATS after failure of urokinase therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/73,77,78\">",
"     73,77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One nonrandomized study compared VATS and conventional thoracotomy after failure of medical treatment (antibiotics with or without drainage) in 39 children over a two-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/79\">",
"     79",
"    </a>",
"    ]. Children admitted during the first year (n = 17) were treated with conventional thoracotomy; those admitted during the second (n = 22) were treated with VATS. Children in the VATS group had shorter duration of analgesia use, postoperative length of hospital stay, time to normothermia, and duration of postoperative chest drains, as well as better cosmesis. Two children in the VATS group required conversion to open thoracotomy for resection of lung parenchyma (for severe necrosis and bronchopleural fistula).",
"   </p>",
"   <p>",
"    Similarly, in a small randomized controlled trial comparing primary VATS and conventional thoracostomy drainage in children with large parapneumonic effusion, children in the VATS group had shorter length of hospital stay and duration of chest tube drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical thoracoscopy has been used as an alternative to VATS in adults with pleural diseases including empyema; this procedure is performed by pulmonologists rather than surgeons and is usually done under light sedation. Medical thoracoscopy is not generally used in children because of lack of safety data and technical difficulties including trocar size. The use of this procedure in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41414?source=see_link\">",
"     \"An overview of medical thoracoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contraindications to VATS include inability to develop a pleural window to access the pleural cavity, the presence of thick pyogenic material,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrotic pleural rinds [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Minithoracotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minithoracotomy achieves debridement and evacuation in a manner similar to VATS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ]. However, minithoracotomy is an open procedure that leaves a small linear scar along the rib line.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Decortication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decortication involves an open posterolateral thoracotomy and excision of the thick fibrous pleural rind with evacuation of pyogenic material. This is a longer and more complicated procedure than minithoracotomy and leaves a larger linear scar along the rib line [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decortication is rarely necessary in children with empyema, since most, if not all, ultimately return to baseline lung function. The BTS guidelines suggest that decortication should be reserved for children with late presenting empyema and significant fibrous pleural rind, complex empyema, and chronic empyema [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,80\">",
"     2,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     MONITORING RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;With appropriate therapy, children with symptomatic parapneumonic effusion can be expected to improve within the first few days of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/6,81\">",
"     6,81",
"    </a>",
"    ]. Those with empyema, particularly empyema caused by S. aureus, anaerobic, or group A streptococcus (S. pyogenes), typically have a more protracted recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response to therapy is characterized by gradual decrease in temperature, white blood cell count, respiratory rate, and heart rate, and improvement in air entry and sense of well being. In patients in whom a chest tube has been placed, diminished chest tube drainage usually also indicates recovery, provided the above-mentioned parameters also are improving. If the child remains febrile or tachypneic, and aeration does not improve, the chest tube may be obstructed or failing to drain because of the development of loculations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/6,7,82-84\">",
"     6,7,82-84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Troubleshooting'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is no indication for routine daily chest radiographs since radiographic findings lag behind clinical status [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/3\">",
"     3",
"    </a>",
"    ]. Chest radiographs should be repeated as indicated by changes in clinical status or after interventions (ie, removal of suction or clamping).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     OUTPATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with parapneumonic effusion or empyema should have chest radiographs (PA and lateral) one to two months after discharge from the hospital. These children should continue to be followed until they have recovered completely and their chest radiograph has returned to near normal, which usually occurs by three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,6,85-87\">",
"     2,6,85-87",
"    </a>",
"    ], but may take as long as 16 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/88\">",
"     88",
"    </a>",
"    ]. They may have residual dullness to percussion and quiet breath sounds over the affected areas related to pleural thickening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,89-92\">",
"     2,89-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation for underlying predisposing conditions, such as immunodeficiency or cystic fibrosis, should be considered in children who have a history of recurrent bacterial infections or poor growth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,15,93\">",
"     2,15,93",
"    </a>",
"    ]. Cystic fibrosis should particularly be considered in young children in whom S. aureus or Pseudomonas aeruginosa was the infecting organism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the marked abnormalities at the time of presentation, and the variety of treatment approaches, the majority of children make a complete recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/17,95\">",
"     17,95",
"    </a>",
"    ]. In retrospective reviews, the percentage of patients who require closed chest tube drainage or other surgical procedures ranges from 62 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/10,81,90,96,97\">",
"     10,81,90,96,97",
"    </a>",
"    ]. There is no evidence that cases caused by antibiotic resistant organisms are associated with poorer outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/71\">",
"     71",
"    </a>",
"    ], although length of stay may be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most children improve with antibiotic therapy and simple drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/17\">",
"     17",
"    </a>",
"    ]. However, early active therapy (ie, chest tube placement plus or minus fibrinolytic therapy or video-assisted thoracoscopy (VATS)) may result in shorter duration of illness and length of hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. Complications such as bronchopleural fistula and tension pneumothorax are rare, but if these complications occur, recovery is prolonged.",
"   </p>",
"   <p>",
"    In the systematic review comparing primary operative and nonoperative therapy described above, the mortality rate for children treated with antibiotics and chest tubes was 3.3 percent; no deaths were reported in the smaller studies of children treated with fibrinolytic therapy, VATS, or thoracotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/17\">",
"     17",
"    </a>",
"    ]. Mortality is higher for children younger than one to two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/10,90,96\">",
"     10,90,96",
"    </a>",
"    ]. Mortality also is increased in patients with underlying disease (eg, aspiration, malnutrition), particularly if treatment is delayed.",
"   </p>",
"   <p>",
"    Long-term follow-up studies suggest that fewer than 10 percent of children have residual symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/8,88,98,99\">",
"     8,88,98,99",
"    </a>",
"    ]. The rate of residual radiologic or pulmonary function abnormalities is higher, but these abnormalities are usually mild [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/8,98,100,101\">",
"     8,98,100,101",
"    </a>",
"    ]. Patients with residual abnormalities in lung function are usually asymptomatic and have normal exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/14/27882/abstract/8,98,99\">",
"     8,98,99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     General overview",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of medical and surgical therapies are available to treat parapneumonic effusions. Although approaches vary, there is a growing consensus that simple effusions should be treated with drainage and antibiotics, and complicated effusions with either early surgical drainage (VATS or mini-thoracotomy) or fibrinolysis and chest tube drainage (",
"      <a class=\"graphic graphic_algorithm graphicRef76277 \" href=\"UTD.htm?18/40/19073\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with loculated parapneumonic effusion who may require further intervention (ie, VATS or fibrinolytic therapy) should undergo transfer to a facility with specialists in pediatric pulmonology, pediatric surgery, and pediatric anesthesia. Early involvement of the surgeon in the decision-making process is beneficial. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that all children with parapneumonic effusion be treated with antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The choice of antibiotic initially is based upon the suspected causative organism and subsequently tailored according to the results of microbiologic testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link&amp;anchor=H12#H12\">",
"       \"Inpatient treatment of pneumonia in children\", section on 'Empiric therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=see_link\">",
"       \"Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that intravenous antibiotics be continued for five days after resolution of fever and oral therapy be continued for at least two weeks thereafter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Free-flowing fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of approaches to the management of children with parapneumonic effusion and free-flowing fluid, none of which has been proven superior to the others in controlled trials. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Algorithmic approaches'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that children who present with moderate or large amounts of free fluid documented by chest radiograph and ultrasonography undergo thoracentesis with drainage of as much fluid as possible (but no more than 10 to 20",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      and observation (with antibiotic therapy) for 48 hours. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Those patients who improve clinically are continued on antibiotic therapy as described above. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Thoracentesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the fever and fluid collection persists and repeat ultrasound shows evidence of loculation, we suggest video-assisted thoracoscopy (VATS) with concurrent insertion of a chest tube (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Video-assisted thoracoscopy (VATS)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Chest tubes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Loculated fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of approaches to the management of children with parapneumonic effusion and loculated fluid, none of which has been proven superior to the others in controlled trials. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Surgical versus medical treatment'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Algorithmic approaches'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients who present with loculated fluid, documented by ultrasonography, undergo primary VATS, with concurrent insertion of a chest tube for diagnosis and treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Fibrinolytic therapy is an alternative for children hospitalized at institutions lacking a pediatric surgeon who is trained in VATS. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Video-assisted thoracoscopy (VATS)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Fibrinolytic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Chest tube removal",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest tube removal is indicated once there is clinical resolution and minimal chest tube drainage. Clinical resolution is indicated by decreased temperature, white blood cell count, respiratory rate, and heart rate, and improved air entry and sense of well being. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Removal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Monitoring response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that children who have been treated for parapneumonic effusion undergo chest radiograph one to two months after discharge from the hospital and continue to be followed until they have recovered completely and their chest radiograph has returned to near normal (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Outpatient follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with parapneumonic effusion who have a history of recurrent bacterial infections, poor growth, or had S. aureus or P. aeruginosa as the infecting organism undergo evaluation for cystic fibrosis and immunodeficiency (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link&amp;anchor=H23#H23\">",
"       \"Approach to the child with recurrent infections\", section on 'Laboratory evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/1\">",
"      Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995; 332:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/2\">",
"      Balfour-Lynn IM, Abrahamson E, Cohen G, et al. BTS guidelines for the management of pleural infection in children. Thorax 2005; 60 Suppl 1:i1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/3\">",
"      Jaff&eacute; A, Balfour-Lynn IM. Management of empyema in children. Pediatr Pulmonol 2005; 40:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/4\">",
"      Givan DC, Eigen H. Common pleural effusions in children. Clin Chest Med 1998; 19:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/5\">",
"      Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.",
"     </a>",
"    </li>",
"    <li>",
"     Panitch HB, Papastamelos C, Schidlow DV. Abnormalities of the pleural space. In: Pediatric Respiratory Medicine, Taussig LM, Landau LI (Eds), Mosby, St. Louis 1999. p.1184.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/7\">",
"      Moran JF. Surgical management of pleural space infections. Semin Respir Infect 1988; 3:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/8\">",
"      McLaughlin FJ, Goldmann DA, Rosenbaum DM, et al. Empyema in children: clinical course and long-term follow-up. Pediatrics 1984; 73:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/9\">",
"      Berger HA, Morganroth ML. Immediate drainage is not required for all patients with complicated parapneumonic effusions. Chest 1990; 97:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/10\">",
"      Meyerovitch J, Shohet I, Rubinstein E. Analysis of thirty-seven cases of pleural empyema. Eur J Clin Microbiol 1985; 4:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/11\">",
"      Kennedy AS, Agness M, Bailey L, White JJ. Decortication for childhood empyema. The primary provider's peccadillo. Arch Surg 1991; 126:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/12\">",
"      Kosloske AM, Cartwright KC. The controversial role of decortication in the management of pediatric empyema. J Thorac Cardiovasc Surg 1988; 96:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/13\">",
"      Gustafson RA, Murray GF, Warden HE, Hill RC. Role of lung decortication in symptomatic empyemas in children. Ann Thorac Surg 1990; 49:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/14\">",
"      Kercher KW, Attorri RJ, Hoover JD, Morton D Jr. Thoracoscopic decortication as first-line therapy for pediatric parapneumonic empyema. A case series. Chest 2000; 118:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/15\">",
"      Hilliard TN, Henderson AJ, Langton Hewer SC. Management of parapneumonic effusion and empyema. Arch Dis Child 2003; 88:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/16\">",
"      Shankar KR, Kenny SE, Okoye BO, et al. Evolving experience in the management of empyema thoracis. Acta Paediatr 2000; 89:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/17\">",
"      Avansino JR, Goldman B, Sawin RS, Flum DR. Primary operative versus nonoperative therapy for pediatric empyema: a meta-analysis. Pediatrics 2005; 115:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/18\">",
"      Kurt BA, Winterhalter KM, Connors RH, et al. Therapy of parapneumonic effusions in children: video-assisted thoracoscopic surgery versus conventional thoracostomy drainage. Pediatrics 2006; 118:e547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/19\">",
"      Sonnappa S, Cohen G, Owens CM, et al. Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema. Am J Respir Crit Care Med 2006; 174:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/20\">",
"      Kokoska ER, Chen MK, New Technology Committee. Position paper on video-assisted thoracoscopic surgery as treatment of pediatric empyema. J Pediatr Surg 2009; 44:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/21\">",
"      Schultz KD, Fan LL, Pinsky J, et al. The changing face of pleural empyemas in children: epidemiology and management. Pediatrics 2004; 113:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/22\">",
"      Carter E, Waldhausen J, Zhang W, et al. Management of children with empyema: Pleural drainage is not always necessary. Pediatr Pulmonol 2010; 45:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/23\">",
"      Gates RL, Caniano DA, Hayes JR, Arca MJ. Does VATS provide optimal treatment of empyema in children? A systematic review. J Pediatr Surg 2004; 39:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/24\">",
"      Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/25\">",
"      Frank AL, Marcinak JF, Mangat PD, Schreckenberger PC. Increase in community-acquired methicillin-resistant Staphylococcus aureus in children. Clin Infect Dis 1999; 29:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/26\">",
"      Alfaro C, Fergie J, Purcell K. Emergence of community-acquired methicillin-resistant Staphylococcus aureus in complicated parapneumonic effusions. Pediatr Infect Dis J 2005; 24:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/27\">",
"      Mishaan AM, Mason EO Jr, Martinez-Aguilar G, et al. Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas. Pediatr Infect Dis J 2005; 24:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/28\">",
"      Hussain FM, Boyle-Vavra S, Bethel CD, Daum RS. Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility. Pediatr Infect Dis J 2000; 19:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/29\">",
"      Trapnell DH, Thurston JG. Unilateral pulmonary oedema after pleural aspiration. Lancet 1970; 1:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/30\">",
"      Pietsch JB, Whitlock JA, Ford C, Kinney MC. Management of pleural effusions in children with malignant lymphoma. J Pediatr Surg 1999; 34:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/31\">",
"      Thomson AH, Hull J, Kumar MR, et al. Randomised trial of intrapleural urokinase in the treatment of childhood empyema. Thorax 2002; 57:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/32\">",
"      Pierrepoint MJ, Evans A, Morris SJ, et al. Pigtail catheter drain in the treatment of empyema thoracis. Arch Dis Child 2002; 87:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/33\">",
"      Stavas J, vanSonnenberg E, Casola G, Wittich GR. Percutaneous drainage of infected and noninfected thoracic fluid collections. J Thorac Imaging 1987; 2:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/34\">",
"      Eibenberger KL, Dock WI, Ammann ME, et al. Quantification of pleural effusions: sonography versus radiography. Radiology 1994; 191:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/35\">",
"      Maier A, Domej W, Anegg U, et al. Computed tomography or ultrasonically guided pigtail catheter drainage in multiloculated pleural empyema: a recommended procedure? Respirology 2000; 5:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/36\">",
"      Hunnam GR, Flower CD. Radiologically-guided percutaneous catheter drainage of empyemas. Clin Radiol 1988; 39:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/37\">",
"      Hyde J, Sykes T, Graham T. Reducing morbidity from chest drains. BMJ 1997; 314:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/38\">",
"      Laws D, Neville E, Duffy J, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the insertion of a chest drain. Thorax 2003; 58 Suppl 2:ii53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/39\">",
"      Nilsson BS, Broberg S, Larsen F, Mellner C. Diagnosis and treatment of empyema. Scand J Respir Dis Suppl 1978; 102:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/40\">",
"      Rosen DA, Morris JL, Rosen KR, et al. Analgesia for pediatric thoracostomy tube removal. Anesth Analg 2000; 90:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/41\">",
"      Scherer LR, West KW, Weber TR, et al. Staphylococcus epidermidis sepsis in pediatric patients: clinical and therapeutic considerations. J Pediatr Surg 1984; 19:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/42\">",
"      Tokuda Y, Matsushima D, Stein GH, Miyagi S. Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysis. Chest 2006; 129:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/43\">",
"      Rosen H, Nadkarni V, Theroux M, et al. Intrapleural streptokinase as adjunctive treatment for persistent empyema in pediatric patients. Chest 1993; 103:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/44\">",
"      Yao CT, Wu JM, Liu CC, et al. Treatment of complicated parapneumonic pleural effusion with intrapleural streptokinase in children. Chest 2004; 125:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/45\">",
"      Krishnan S, Amin N, Dozor AJ, Stringel G. Urokinase in the management of complicated parapneumonic effusions in children. Chest 1997; 112:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/46\">",
"      Kogut KA, Lobe TE. Urokinase in the management of complicated parapneumonic effusions in children. Clin Pediatr (Phila) 1999; 38:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/47\">",
"      Weinstein M, Restrepo R, Chait PG, et al. Effectiveness and safety of tissue plasminogen activator in the management of complicated parapneumonic effusions. Pediatrics 2004; 113:e182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/48\">",
"      Wells RG, Havens PL. Intrapleural fibrinolysis for parapneumonic effusion and empyema in children. Radiology 2003; 228:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/49\">",
"      Barbato A, Panizzolo C, Monciotti C, et al. Use of urokinase in childhood pleural empyema. Pediatr Pulmonol 2003; 35:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/50\">",
"      Kili&ccedil; N, Celebi S, G&uuml;rpinar A, et al. Management of thoracic empyema in children. Pediatr Surg Int 2002; 18:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/51\">",
"      Kornecki A, Sivan Y. Treatment of loculated pleural effusion with intrapleural urokinase in children. J Pediatr Surg 1997; 32:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/52\">",
"      Ulk&uuml; R, Onen A, Onat S, et al. Intrapleural fibrinolytic treatment of multiloculated pediatric empyemas. Pediatr Surg Int 2004; 20:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/53\">",
"      Gates RL, Hogan M, Weinstein S, Arca MJ. Drainage, fibrinolytics, or surgery: a comparison of treatment options in pediatric empyema. J Pediatr Surg 2004; 39:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/54\">",
"      Barnes NP, Hull J, Thomson AH. Medical management of parapneumonic pleural disease. Pediatr Pulmonol 2005; 39:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/55\">",
"      Singh M, Mathew JL, Chandra S, et al. Randomized controlled trial of intrapleural streptokinase in empyema thoracis in children. Acta Paediatr 2004; 93:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/56\">",
"      Grewal H, Jackson RJ, Wagner CW, Smith SD. Early video-assisted thoracic surgery in the management of empyema. Pediatrics 1999; 103:e63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/57\">",
"      Bouros D, Schiza S, Patsourakis G, et al. Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions: a prospective, double-blind study. Am J Respir Crit Care Med 1997; 155:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/58\">",
"      Maskell NA, Davies CW, Nunn AJ, et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005; 352:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/59\">",
"      St Peter SD, Tsao K, Spilde TL, et al. Thoracoscopic decortication vs tube thoracostomy with fibrinolysis for empyema in children: a prospective, randomized trial. J Pediatr Surg 2009; 44:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/60\">",
"      Hawkins JA, Scaife ES, Hillman ND, Feola GP. Current treatment of pediatric empyema. Semin Thorac Cardiovasc Surg 2004; 16:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/61\">",
"      Stringel G, Hartman AR. Intrapleural instillation of urokinase in the treatment of loculated pleural effusions in children. J Pediatr Surg 1994; 29:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/62\">",
"      Alfageme I, V&aacute;zquez R. Ventricular fibrillation after intrapleural urokinase. Intensive Care Med 1997; 23:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/63\">",
"      Laisaar T, Pullerits T. Effect of intrapleural streptokinase administration on antistreptokinase antibody level in patients with loculated pleural effusions. Chest 2003; 123:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/64\">",
"      Jamal M, Reebye SC, Zamakhshary M, et al. Can we predict the failure of thoracostomy tube drainage in the treatment of pediatric parapneumonic collections? J Pediatr Surg 2005; 40:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/65\">",
"      Chen LE, Langer JC, Dillon PA, et al. Management of late-stage parapneumonic empyema. J Pediatr Surg 2002; 37:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/66\">",
"      Kern JA, Rodgers BM. Thoracoscopy in the management of empyema in children. J Pediatr Surg 1993; 28:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/67\">",
"      Angelillo Mackinlay TA, Lyons GA, Chimondeguy DJ, et al. VATS debridement versus thoracotomy in the treatment of loculated postpneumonia empyema. Ann Thorac Surg 1996; 61:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/68\">",
"      Cohen G, Hjortdal V, Ricci M, et al. Primary thoracoscopic treatment of empyema in children. J Thorac Cardiovasc Surg 2003; 125:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/69\">",
"      Klena JW, Cameron BH, Langer JC, et al. Timing of video-assisted thoracoscopic debridement for pediatric empyema. J Am Coll Surg 1998; 187:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/70\">",
"      Merry CM, Bufo AJ, Shah RS, et al. Early definitive intervention by thoracoscopy in pediatric empyema. J Pediatr Surg 1999; 34:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/71\">",
"      Quintero DR, Fan LL. Approach to pleural effusions and empyemas. Paediatr Respir Rev 2004; 5 Suppl A:S151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/72\">",
"      Doski JJ, Lou D, Hicks BA, et al. Management of parapneumonic collections in infants and children. J Pediatr Surg 2000; 35:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/73\">",
"      Jaff&eacute; A, Cohen G. Thoracic empyema. Arch Dis Child 2003; 88:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/74\">",
"      Silen ML, Weber TR. Thoracoscopic debridement of loculated empyema thoracis in children. Ann Thorac Surg 1995; 59:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/75\">",
"      Stovroff M, Teague G, Heiss KF, et al. Thoracoscopy in the management of pediatric empyema. J Pediatr Surg 1995; 30:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/76\">",
"      Yim AP, Low JM, Ng SK, et al. Video-assisted thoracoscopic surgery in the paediatric population. J Paediatr Child Health 1995; 31:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/77\">",
"      Bouros D, Antoniou KM, Chalkiadakis G, et al. The role of video-assisted thoracoscopic surgery in the treatment of parapneumonic empyema after the failure of fibrinolytics. Surg Endosc 2002; 16:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/78\">",
"      Sit SC, Cohen G, Jaffe A. Urokinase in the treatment of childhood empyema. Thorax 2003; 58:93; author reply 93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/79\">",
"      Subramaniam R, Joseph VT, Tan GM, et al. Experience with video-assisted thoracoscopic surgery in the management of complicated pneumonia in children. J Pediatr Surg 2001; 36:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/80\">",
"      Fraga JC, Kim P. [Surgical treatment of parapneumonic pleural effusion and its complications]. J Pediatr (Rio J) 2002; 78 Suppl 2:S161.",
"     </a>",
"    </li>",
"    <li>",
"     Wheeler JG, Jacobs RF. Pleural effusions and empyema. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.325.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/82\">",
"      Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med 1980; 69:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/83\">",
"      Potts DE, Taryle DA, Sahn SA. The glucose-pH relationship in parapneumonic effusions. Arch Intern Med 1978; 138:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/84\">",
"      Orringer MB. Thoracic empyema--back to basics. Chest 1988; 93:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/85\">",
"      Chan PW, Crawford O, Wallis C, Dinwiddie R. Treatment of pleural empyema. J Paediatr Child Health 2000; 36:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/86\">",
"      Gocmen A, Kiper N, Toppare M, et al. Conservative treatment of empyema in children. Respiration 1993; 60:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/87\">",
"      Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66 Suppl 2:ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/88\">",
"      Satish B, Bunker M, Seddon P. Management of thoracic empyema in childhood: does the pleural thickening matter? Arch Dis Child 2003; 88:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/89\">",
"      Hartl H. Pleuropulmonary suppurations. Prog Pediatr Surg 1977; 10:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/90\">",
"      Freij BJ, Kusmiesz H, Nelson JD, McCracken GH Jr. Parapneumonic effusions and empyema in hospitalized children: a retrospective review of 227 cases. Pediatr Infect Dis 1984; 3:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/91\">",
"      Bartlett JG. Bacterial infections of the pleural space. Semin Respir Infect 1988; 3:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/92\">",
"      Wise MB, Beaudry PH, Bates DV. Long-term follow-up of staphylococcal pneumonia. Pediatrics 1966; 38:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/93\">",
"      Khakoo GA, Goldstraw P, Hansell DM, Bush A. Surgical treatment of parapneumonic empyema. Pediatr Pulmonol 1996; 22:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/94\">",
"      Bush A. The treatment of empyema in childhood. J R Soc Med 1994; 87:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/95\">",
"      Cohen E, Mahant S, Dell SD, et al. The long-term outcomes of pediatric pleural empyema: a prospective study. Arch Pediatr Adolesc Med 2012; 166:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/96\">",
"      Hoff SJ, Neblett WW, Edwards KM, et al. Parapneumonic empyema in children: decortication hastens recovery in patients with severe pleural infections. Pediatr Infect Dis J 1991; 10:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/97\">",
"      Mangete ED, Kombo BB, Legg-Jack TE. Thoracic empyema: a study of 56 patients. Arch Dis Child 1993; 69:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/98\">",
"      Redding GJ, Walund L, Walund D, et al. Lung function in children following empyema. Am J Dis Child 1990; 144:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/99\">",
"      Sarihan H, Cay A, Aynaci M, et al. Empyema in children. J Cardiovasc Surg (Torino) 1998; 39:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/100\">",
"      Murphy D, Lockhart CH, Todd JK. Pneumococcal empyema: outcome of medical management. Am J Dis Child 1980; 134:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/14/27882/abstract/101\">",
"      Santosham M, Chipps BE, Strife JL, Moxon ER. Sequelae of H. influenzae type b empyema. J Pediatr 1979; 95:160.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6345 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-1745D172DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27882=[""].join("\n");
var outline_f27_14_27882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Surgical versus medical treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Algorithmic approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANTIBIOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Community-acquired Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      THORACENTESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CHEST TUBES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Size of tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Troubleshooting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      FIBRINOLYTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Technique and dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SURGICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Video-assisted thoracoscopy (VATS)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Minithoracotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Decortication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      MONITORING RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      OUTPATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      PROGNOSIS AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      General overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Free-flowing fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Loculated fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Chest tube removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6345\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6345|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/40/19073\" title=\"algorithm 1\">",
"      Management of a large parapneumonic effusion in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/48/30478\" title=\"algorithm 2\">",
"      Management of a small parapneumonic effusion in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6345|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/50/21292\" title=\"table 1\">",
"      Systematic review empyema Rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/34/42540\" title=\"table 2\">",
"      BTS guidelines rx empyema child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41414?source=related_link\">",
"      An overview of medical thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=related_link\">",
"      Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=related_link\">",
"      Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=related_link\">",
"      Imaging of pleural effusions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=related_link\">",
"      Inpatient treatment of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_14_27883="Platelet P2Y12 receptor blocker loading doses in acute STEMI";
var content_f27_14_27883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Platelet P2Y12 receptor blocker loading doses in acute STEMI",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Reperfusion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age (years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preferred drug (loading dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Yes",
"       </td>",
"       <td rowspan=\"2\">",
"        PCI",
"       </td>",
"       <td rowspan=\"2\">",
"        ALL",
"       </td>",
"       <td>",
"        Ticagrelor loading dose 180 mg or prasugrel loading dose 60 mg, in patients without contraindications*. Both are preferred to clopidogrel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clopidogrel loading dose 300-600 mg (600 mg is preferred), in patients for whom ticagrelor or prasugrel is not chosen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Fibrinolysis",
"       </td>",
"       <td>",
"        &lt;75",
"       </td>",
"       <td>",
"        Clopidogrel 300 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;75",
"       </td>",
"       <td>",
"        Clopidogrel 75 mg",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        ALL",
"       </td>",
"       <td>",
"        Ticagrelor 180 mg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Absolute contraindications to prasugrel include a history of stroke or transient ischemic attack (T.I.A.) or active pathological bleeding. Weight &lt;60 kg and age &ge;75 years are relative contraindications.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27883=[""].join("\n");
var outline_f27_14_27883=null;
var title_f27_14_27884="Old single agts chemo";
var content_f27_14_27884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Studies evaluating old single agents chemotherapy in locally advanced and metastatic esophageal and gastric cancers*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cancer type",
"      </td>",
"      <td class=\"subtitle1\">",
"       Author",
"      </td>",
"      <td class=\"subtitle1\">",
"       N",
"      </td>",
"      <td class=\"subtitle1\">",
"       RR (percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       5-FU",
"      </td>",
"      <td>",
"       Esophageal",
"      </td>",
"      <td>",
"       Ezdinli, E; 1980",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       17",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastric",
"      </td>",
"      <td>",
"       Earl, H; 1984",
"      </td>",
"      <td>",
"       457",
"      </td>",
"      <td>",
"       20",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Mitomycin",
"      </td>",
"      <td>",
"       Esophageal",
"      </td>",
"      <td>",
"       Whittington, R; 1970",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       35",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastric",
"      </td>",
"      <td>",
"       Earl, H; 1984",
"      </td>",
"      <td>",
"       189",
"      </td>",
"      <td>",
"       29",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Doxorubicin",
"      </td>",
"      <td>",
"       Esophageal",
"      </td>",
"      <td>",
"       Ezdinli, E; 1980",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastric",
"      </td>",
"      <td>",
"       Earl, H; 1984",
"      </td>",
"      <td>",
"       180",
"      </td>",
"      <td>",
"       17",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Cisplatin",
"      </td>",
"      <td>",
"       Esophageal",
"      </td>",
"      <td>",
"       Bleiberg, H; 1997",
"      </td>",
"      <td>",
"       37",
"      </td>",
"      <td>",
"       19",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastric",
"      </td>",
"      <td>",
"       Beer, M; 1983",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       22",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Methotrexate",
"      </td>",
"      <td>",
"       Esophageal",
"      </td>",
"      <td>",
"       Ezdinli, E; 1980",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       13",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastric",
"      </td>",
"      <td>",
"       Bruckner, H; 1982",
"      </td>",
"      <td>",
"       28",
"      </td>",
"      <td>",
"       11",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Bleomycin",
"      </td>",
"      <td>",
"       Esophageal",
"      </td>",
"      <td>",
"       Br Med J; 1970",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       50",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastric",
"      </td>",
"      <td>",
"       Br Med J; 1970",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    *In many cases, response rates were not determined by modern CT-based criteria.",
"    <div class=\"footnotes\">",
"     N: number of patients; RR: objective response rate.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Fidias, P, El-Karak, FR.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27884=[""].join("\n");
var outline_f27_14_27884=null;
var title_f27_14_27885="Prostate weight and age";
var content_f27_14_27885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Age-related increase in prostate weight",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 241px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Average prostatic weights (mean &plusmn; standard error of the mean in gray) are presented for 10-year intervals. The prostate glands were obtained at autopsy from 925 samples collected from five separate studies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Berry, SJ, Coffey, DS, Walsh, PC, et al, J Urol 1984; 132:474.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27885=[""].join("\n");
var outline_f27_14_27885=null;
var title_f27_14_27886="Regulation contractile state";
var content_f27_14_27886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Major mechanisms regulating the myocardial contractile state",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 285px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The contractile state of the myocardium is primarily modulated by three mechanisms involving calcium (Ca2+): the intracellular handling of free ionized Ca2+, the interaction of Ca2+ with the contractile elements (actin-myosin), and the interaction of Ca2+ with troponin C (TnC). The dashed line connecting TnC to actin depicts the inhibitory action of troponin-tropomyosin complex on the actin-myosin interaction. This inhibition is removed and cross-bridges are allowed to attach when Ca2+ binds to TnC.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27886=[""].join("\n");
var outline_f27_14_27886=null;
var title_f27_14_27887="Yankauer suction device";
var content_f27_14_27887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Yankauer suction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This device has an easily accessible shutoff valve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_14_27887=[""].join("\n");
var outline_f27_14_27887=null;
